A RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED, 
5-WAY CROSSOVER STUDY TO DETERMINE THE ABUSE POTENTIAL OF
ORALLY ADMINISTERED GABAPENTIN ENACARBIL IMMEDIATE RELEASE 
CAPSULES IN HEALTHY, NONDEPENDENT, RECREATIONAL DRUG USERS 
WITH SEDATIVE EXPERIENCE 
Protocol Number: AR26.3031.[ADDRESS_709700] Number: ABO-P1-[ADDRESS_709701]: Gabapentin Enacarbil Immediate Release 
Capsules 
Phase of Development: Not applicable 
Sponsor: Arbor Pharmaceuticals, LLC 
[ADDRESS_709702] 
Atlanta, GA [ZIP_CODE] [LOCATION_003] 
COMPLIANCE 
The study will be conducted in accordance with standards of Good Clinical Practice, as defined by [CONTACT_543640] . 
Protocol Version Date 
3.0 (Amendment 02) 09AUG2021 
 
 
CONFIDENTIALITY STATEMENT 
The information provided in this document is strictly confidential and is available for review to investigator(s) 
and to the appropriate Independent Ethics Committee (IEC) or Institutional Review Board (IRB). It may not be 
used, divulged, published or otherwise disclosed without the written authorization from Altasciences or the 
sponsor. 
ClinicalTrials.gov: [STUDY_ID_REMOVED]
Protocol No: AR26.3031.[ADDRESS_709703] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 2 of 81
PROTOCOL AMENDMENT 02 – SUMMARY OF CHANGES 
Description of Change Made Section/Location Rationale 
Added continuous monitoring of 
oxygen saturation from 1 hour 
before up to 6 hours after drug 
administration in the 
Qualification Phase. Table 1 (Schedule of 
Activities) Requested by [CONTACT_5030] 
(IRB). 
 
Protocol No: AR26.3031.[ADDRESS_709704] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 3 of 81
TABLE OF CONTENTS 
PROTOCOL AMENDMENT 02 – SUMMARY OF CHANGES ........................................................................... 2  
TABLE OF CONTENTS ............................................................................................................................................ 3  
STUDY SYNOPSIS ..................................................................................................................................................... 7  
INVESTIGATOR AND STUDY ADMINISTRATIVE STRUCTURE ................................................................ 14  
1 INTRODUCTION .............................................................................................................................................. 16  
1.1 Background ................................................................................................................................................... 16  
1.2 Study Rationale ............................................................................................................................................. 16  
1.3 Rationale for Dose Selection ......................................................................................................................... 19  
1.4 Risk/Benefit Assessment ............................................................................................................................... [ADDRESS_709705] Treatment Administration..................................................................................................... 30  
4.5 Lifestyle and/or Dietary Requirements ......................................................................................................... [ADDRESS_709706] Management ............................................................................................................ 32  
5.2.1 Packaging, Labeling and Dispensing ..................................................................................................... 32  
5.2.2 Storage and Handling ............................................................................................................................. 33  
5.2.3 Method of Assigning Subjects to Treatment Groups ............................................................................. 33  
[IP_ADDRESS] Qualification Phase ......................................................................................................................... 33  
[IP_ADDRESS] Treatment Phase .............................................................................................................................. 33  
5.2.4 Blinding .................................................................................................................................................. 35  
Protocol No: AR26.3031.[ADDRESS_709707] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 4 of 81
5.2.5 Study Drug Accountability..................................................................................................................... 35  
5.3 Administration of Study Drug, Meals and Fluids .......................................................................................... 35  
5.3.1 Treatment Compliance ........................................................................................................................... 35  
5.4 Other Protocol Restrictions ........................................................................................................................... 36  
6 STUDY PROCEDURES .................................................................................................................................... 36  
6.1 Safety Assessments ....................................................................................................................................... 36  
6.1.1 Medical History ...................................................................................................................................... 36  
6.1.2 Recreational Alcohol/Drug Use ............................................................................................................. 37  
6.1.3 Physical Examination ............................................................................................................................. 37  
6.1.4 Vital Signs .............................................................................................................................................. 37  
[IP_ADDRESS] Continuous and Spot Oxygen Saturation ........................................................................................ 37  
[IP_ADDRESS] Continuous and Spot End-Tidal CO 2 .............................................................................................. 38  
[IP_ADDRESS] Continuous and Spot Respi[INVESTIGATOR_13581] ........................................................................................... 38  
6.1.5 12-Lead Electrocardiogram .................................................................................................................... 38  
6.1.6 Laboratory Evaluations .......................................................................................................................... 38  
6.1.7 Columbia Suicide Severity Rating Scale (C-SSRS) ............................................................................... 39  
6.1.8 Assessment of Respi[INVESTIGATOR_47703] .................................................................................................. 39  
6.1.9 Rescue Therapy ...................................................................................................................................... 39  
6.2 Pharmacokinetic Assessments ....................................................................................................................... 40  
6.2.1 Pharmacokinetic Sample Processing, Storage and Shippi[INVESTIGATOR_007] .................................................................. 41  
6.3 Pharmacodynamic Assessments .................................................................................................................... 41  
6.3.1 Subjective Effects................................................................................................................................... 41  
[IP_ADDRESS] Visual Analogue Scales .................................................................................................................. 41  
[IP_ADDRESS] Questionnaires ................................................................................................................................. 43  
6.3.2 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) .................................................... 44  
7 ADVERSE EVENTS DOCUMENTATION .................................................................................................... 45  
7.1 Definitions ..................................................................................................................................................... 45  
7.2 Severity Assessment ...................................................................................................................................... 46  
7.3 Causality Assessment .................................................................................................................................... 46  
7.4 Adverse Event Monitoring ............................................................................................................................ 47  
7.5 Reporting of Pregnancy ................................................................................................................................. 48  
7.6 Serious Adverse Event Reporting ................................................................................................................. 48  
8 DATA ANALYSIS AND STATISTICAL METHODS ................................................................................... 49  
8.1 Analysis Populations ..................................................................................................................................... 49  
8.1.1 Qualification Phase ................................................................................................................................ 49  
[IP_ADDRESS] Qualification Randomized Population ............................................................................................ 49  
Protocol No: AR26.3031.[ADDRESS_709708] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 5 of 81
[IP_ADDRESS] Qualification Safety Population ...................................................................................................... 49  
8.1.2 Treatment Phase ..................................................................................................................................... 49  
[IP_ADDRESS] Randomized Population .................................................................................................................. 49  
[IP_ADDRESS] Safety Population ............................................................................................................................ 49  
[IP_ADDRESS] Completer Population ..................................................................................................................... 49  
[IP_ADDRESS] Modified Completer Population ...................................................................................................... 49  
[IP_ADDRESS] Pharmacokinetic (PK) Population ................................................................................................... 50  
8.2 Appropriateness of Measures ........................................................................................................................ 50  
8.3 Missing Values .............................................................................................................................................. 50  
8.4 Demographic Data and Other Baseline Characteristics ................................................................................. 51  
8.4.1 Qualification Phase ................................................................................................................................ 51  
8.4.2 Treatment Phase ..................................................................................................................................... 51  
8.5 Pharmacodynamics ........................................................................................................................................ 51  
8.5.1 Pharmacodynamic Endpoints ................................................................................................................. 51  
8.5.2 Pharmacodynamic Statistical Methodology ........................................................................................... 52  
[IP_ADDRESS] Primary Analysis ............................................................................................................................. 52  
[IP_ADDRESS] Secondary Analysis ......................................................................................................................... 58  
8.6 Pharmacokinetics .......................................................................................................................................... 59  
8.6.1 Measurements Below the Lower Limit of Quantitation ......................................................................... 59  
8.6.2 Actual Time ............................................................................................................................................ 59  
8.6.3 Noncompartmental Analysis (NCA) ...................................................................................................... 59  
8.6.4 Pharmacokinetic Statistical Methodology .............................................................................................. 60  
[IP_ADDRESS] Descriptive Statistics ....................................................................................................................... 60  
[IP_ADDRESS] Statistical Analysis .......................................................................................................................... 60  
8.7 Safety............................................................................................................................................................. 60  
8.7.1 Safety Endpoints .................................................................................................................................... 60  
8.7.2 Safety Analysis....................................................................................................................................... 61  
8.7.3 Safety Statistical Methodology .............................................................................................................. 61  
[IP_ADDRESS] Qualification Phase ......................................................................................................................... 61  
[IP_ADDRESS] Treatment Phase .............................................................................................................................. 61  
8.8 Planned Interim Analyses .............................................................................................................................. 61  
8.9 Determination of Sample Size ....................................................................................................................... 62  
9 REFERENCES ................................................................................................................................................... 63  
10 APPENDIX 1: ETHICS ..................................................................................................................................... [ADDRESS_709709] of the Study ......................................................................................................................... 66  
Protocol No: AR26.3031.[ADDRESS_709710] Number: ABO-P1-[ADDRESS_709711] Confidentiality .................................................................................................................................. 66  
11 APPENDIX 2: DATA COLLECTION, RETENTION, AND MONITORING ............................................ [ADDRESS_709712] Retention ........................................................................................................................................... 68  
11.5 Monitoring of the Study ................................................................................................................................ 68  
12 APPENDIX 3: ADMINISTRATIVE PROCEDURES .................................................................................... 69  
12.1 Liabilities ....................................................................................................................................................... 69  
12.2 Adherence to Protocol ................................................................................................................................... 69  
12.3 Statement of Investigator ............................................................................................................................... 69  
12.4 Delegation of Investigator Duties .................................................................................................................. 69  
12.5 Premature Termination or Suspension of a Study ......................................................................................... 69  
13 APPENDIX 4: PROTOCOL REVIEW AND APPROVALS ......................................................................... 70  
14 APPENDIX 5: LIST OF ABBREVIATIONS .................................................................................................. 72  
15 APPENDIX 6: CLINICAL LABORATORY EVALUATIONS ..................................................................... 75  
16 APPENDIX 7: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) –
BASELINE/SCREENING VERSION ..................................................................................................................... 76  
17 APPENDIX 8: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) –SINCE LAST VISIT 
VERSION ................................................................................................................................................................... [ADDRESS_709713] OF IN-TEXT TABLES 
Table 1. Schedule of Activities ..................................................................................................... 10  
Table 2. Sample Qualification Phase Sequences .......................................................................... 33  
Table 3. Sample Treatment Phase Sequences ............................................................................... 34  
Table 4. Pharmacokinetic Blood Sampling Schedule ................................................................... 40  
Table 5. Visual Analog Scale (VAS) Descriptions ....................................................................... 42  
Table 6. Adverse Event Relationship to Study Drug .................................................................... 47  
Table 7. Pharmacodynamic Endpoints ......................................................................................... 52  
Table 8. Pharmacokinetic Parameters ........................................................................................... 60  
Protocol No: AR26.3031.[ADDRESS_709714] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 7 of 81
STUDY SYNOPSIS 
Name [CONTACT_44713]/Company: Arbor Pharmaceuticals, LLC 
Name [CONTACT_35215]: Gabapentin enacarbil immediate release capsules (GE-IR) 
Title of Study: A Randomized, Double-Blind, Active- and Placebo-Controlled, 5-Way Crossover 
Study to Determine the Abuse Potential of Orally Administered Gabapentin 
Enacarbil Immediate Release Capsules in Healthy, Nondependent, Recreational 
Drug Users with Sedative Experience 
Study Development 
Phase: Not applicable 
Objectives: Primary Objective: 
To evaluate the abuse potential of single oral doses of GE-IR relative to 
alprazolam and placebo, when administered to nondependent recreational drug 
users with sedative drug use experience. 
Secondary Objectives: 
To evaluate the pharmacokinetics (PK) of gabapentin from GE-IR when 
administered to nondependent, recreational drug users with sedative drug use 
experience. 
To evaluate the effects on safety and tolerability of single oral doses of GE-IR 
relative to alprazolam and placebo, when administered to nondependent, 
recreational drug users with sedative drug use experience. 
Endpoints: Pharmacodynamic (PD) Endpoints: 
The primary endpoint of this study will be maximum (peak) effect (E max) over 
24 hours for Drug Liking (“at this moment”), assessed on a bipolar (0 to 
100 points) visual analog scale (VAS). 
Key Secondary PD endpoints will be: 
 Overall Drug Liking VAS (E max) 
 Take Drug Again VAS (E max) 
 High VAS (E max) 
Non-Key Secondary PD endpoints will be: 
Balance of Effects 
 Drug Liking VAS (time of maximum effect [TE max], minimum effect 
[Emin], time of minimum effect [TE min], and time-averaged area under the 
effect-time curve [TA_AUE]) 
Positive Effects 
 High VAS (TE max, and TA_AUE) 
 Good Effects VAS (E max, TEmax, and TA_AUE) 
Negative Effects 
 Bad Effects VAS (E max, TEmax, and TA_AUE) 
Protocol No: AR26.3031.[ADDRESS_709715] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 8 of 81
Other Subjective Effects 
 Any Effects VAS (E max, TEmax, and TA_AUE) 
 Feeling Drunk VAS (E max, TEmax, and TA_AUE) 
 Drowsiness/Alertness VAS (E min, TEmin, and time-averaged area over the 
effect-time curve [TA_AOE]) 
 Relaxation/Agitation (E min, TEmin, and TA_AOE) 
 Addiction Research Center Inventory (ARCI) Morphine-Benzedrine 
Group (MBG) Scale (E max, TEmax, and TA_AUE) 
 ARCI Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) Scale 
(Emax, TEmax, and TA_AUE) 
Observer Assessments 
 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) (E min, 
CFBmin, and TA_AOE) 
Pharmacokinetic Endpoints: 
Pharmacokinetic parameters of GE-IR include maximum observed concentration 
(Cmax), time of maximum observed concentration (T max), time of last measurable 
observed concentration (T last), and area under the curve from time [ADDRESS_709716] 
measurable observed concentration (AUC 0-T). 
Safety Endpoints: 
Endpoints will include a summary of the incidence of adverse events (AEs), 
serious adverse events (SAEs), as well as descriptive summary and statistics of 
the safety parameters. 
Safety parameters will include clinical laboratory values, vital signs (i.e., systolic 
and diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral temperature, oxygen 
saturation [SpO 2]), continuous SpO 2 monitoring, continuous End Tidal CO 2 
monitoring, electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale 
(C-SSRS), and physical examination findings. Study Product, 
Dose, and Mode of 
Administration 
(proposed): Gabapentin Enacarbil Immediate Release (GE-IR) Capsules 
Manufacturer: Arbor Pharmaceuticals, LLC 
Mode of administration: Doses of GE-IR capsules including 200 mg (1 × 200 mg 
capsule), 450 mg (2 × 225 mg capsules) and 700 mg (3 × 233.3 mg capsules) will 
be administered orally according to the randomization schedule during the 
Treatment phase. 
Active Control, 
Dose, and Mode of 
Administration: Over-encapsulated Xanax (alprazolam) 1 mg tablets 
Manufacturer: [COMPANY_007], Inc. 
Mode of administration: Single doses of 2 mg alprazolam (2 × 1 mg tablets 
over-encapsulated in one Swedish Orange Opaque AAEL-DB capsule) will be 
administered orally according to the randomization schedule during the 
Qualification and Treatment phases. 
Placebo, Dose, and 
Mode of 
Administration: Placebo-to-match GE-IR capsules 
Manufacturer: Arbor Pharmaceuticals, LLC 
Mode of administration: Single doses of placebo-to-match GE-IR (233.3 mg 
Protocol No: AR26.3031.[ADDRESS_709717] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 9 of 81
over-encapsulated placebo) capsule in one Swedish Orange Opaque AAEL-DB 
capsule) capsule(s) will be administered orally according to the randomization 
schedule during the Treatment phase. 
Over-encapsulated placebo-to-match alprazolam 
Mode of administration: Single doses of placebo-to-match alprazolam (2 × over-
encapsulated placebo tablets in one Swedish Orange Opaque AAEL-DB capsule) 
will be administered orally according to the randomization schedule during the 
Qualification and Treatment phases. 
Study Design: This study will be a randomized, double-blind, active- and placebo-controlled, 
5-way crossover study to determine the abuse potential of GE-IR relative to 
alprazolam and placebo, in nondependent, recreational drug users with sedative 
drug use experience. 
This study will consist of 3 phases: screening, qualification and treatment. 
Duration of 
Treatment and 
Subject 
Confinement: Duration of clinical trial (per subject): 
Screening: Day -30 to Day -2 
Qualification phase: Subjects will be confined to the clinical site from Day -[ADDRESS_709718] dose of the Treatment phase. 
Treatment phase: Subjects will be confined to the clinical site from Treatment 
phase Day -1 until Day 14. 
Total study duration: up to approximately 49 days (including screening)  
Study Population: Healthy, male and female nondependent, recreational drug users with sedative 
drug experience, aged 18 to 55 years. 
Planned Number 
of Subjects: Approximately 60 subjects will be randomized into the Treatment phase, such 
that approximately 48 subjects complete the Treatment phase of the study.  
Bioanalysis: Gabapentin plasma concentrations will be measured by a validated bioanalytical 
method. 
Pharmacodynamic 
Analysis: For each PD endpoint, descriptive statistics by [CONTACT_543641], 
and inferential analysis using a mixed-effects model, a paired t-test or the sign 
test, as appropriate, will be performed. Pharmacokinetic 
Analysis: PK analyses will be performed by [CONTACT_105]-compartmental analysis (NCA) and C max, 
Tmax, Tlast, and AUC 0-T will be estimated for gabapentin. 
The PK analysis will be further detailed in the statistical analysis plan (SAP). 
Statistical 
Analysis: The PD and PK statistical analyses are discussed in sections 8.5 and [IP_ADDRESS], 
respectively, and will be fully detailed in the SAP. 
Safety Analysis: The safety analysis is discussed in section 8.7 and will be fully detailed in the 
SAP. 
 
 
Protocol No: AR26.3031.[ADDRESS_709719] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 13 of 81
l Additional training sessions may be conducted as needed. Training will be conducted on Day -1 of the Qualification Phase and, if applicable, upon re-admission to the Treatment 
Phase. 
m Subjective measures will be evaluated as follows: 
Category Evaluations Phase Timepoints 
Drug-specific 
VAS Drug Liking, Good Drug Effects, 
Bad Drug Effects, and Any Drug 
Effects Qualification phase approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose Treatment phase approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours postdose 
Overall Drug Liking and Take Drug 
Again Qualification and 
treatment phases approximately 12 and 24 hours postdose 
Other VAS High, Feeling Drunk, 
Relaxation/Agitation, and 
Drowsiness/Alertness Qualification phase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose 
Treatment phase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours 
postdose 
ARCI Scales Morphine-Benzedrine Group 
(MBG) and Pentobarbital–
Chlorpromazine–Alcohol Group 
(PCAG) Qualification phase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose 
Treatment phase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours 
postdose 
n Conducted during the Qualification and Treatment phases within 1 hour prior to dosing and approximately (±15 minutes) at 0.5, 1, 1.5, 2 hours postdose and approximately 
(±30 minutes) at 3, 4, and 6 hours postdose. 
o Blood samples will be collected as indicated in Table 4. When clinical activities are scheduled to occur at the same time, pharmacodynamic data collection (vital signs then 
subjective measures) is to be prioritized, followed by [CONTACT_483280]. 
p If subjects are discharged between the Qualification and Treatment phases, noted discharge procedures will be performed on Day [ADDRESS_709720] dose of the Treatment phase.  
q Randomization will be performed for Qualification phase only on Day -1 of the Qualification phase then, subjects who meet qualification criteria will be randomized for the 
Treatment phase on Day -1 of the Treatment phase. 
r Subjects administered 2 mg alprazolam or placebo according to randomization with a minimum of 48 hours between doses during the Qualification phase. 
s Subjects administered 200 mg GE-IR, 450 mg GE-IR, 700 mg GE-IR, or GE-IR placebo, and 2 mg alprazolam or alprazolam placebo (section 3.2) according to randomization 
with a minimum washout period of 3 days between doses. 
t Covid-19 testing will be performed prior to admission for the Qualification Phase and, if applicable, upon re-admission for the Treatment Phase. 
u Oxygen saturation (SpO 2) will be monitored continuously from 1 hour prior to each drug administration (alprazolam or placebo) and will continue for up to 6 hours following 
each drug administration, or longer if deemed medically necessary. 
 
Protocol No: AR26.3031.[ADDRESS_709721] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 14 of 81
INVESTIGATOR AND STUDY ADMINISTRATIVE STRUCTURE 
SPONSOR’S CONTACT:   
 
[CONTACT_543642], LLC 
 
 
 
 
PRINCIPAL INVESTIGATOR:   
[INVESTIGATOR_85291], Inc. 
 
 
CLINICAL RESEARCH UNIT:  Altasciences Clinical Kansas, Inc 
 
 
 
 
 
 
 
 
CLINICAL LABORATORY  
FACILITY:    Quest Diagnostics 
 
 
BIOANALYTICAL FACILITY: Altasciences 
 
 
 
MEDICAL WRITING &  
SCIENTIFIC AFFAIRS:  Altasciences 
 
 
 
STATISTICAL FACILITY: Altasciences 
 
 
 
DATA MANAGEMENT FACILITY: Altasciences 
 
 

Protocol No: AR26.3031.[ADDRESS_709722] Number: ABO-P1-[ADDRESS_709723] MANAGEMENT:  Altasciences 
 
 
 
 
COGNITIVE TESTS: Cambridge Cognition 
 
 
 
MONITORING: Randstad Life Sciences 
 
 

Protocol No: AR26.3031.[ADDRESS_709724] Number: ABO-P1-[ADDRESS_709725] prodrug in blood is transient and 
≤2% of the corresponding gabapentin level. As a prodrug of gabapentin, its therapeutic effects in 
restless legs syndrome (RLS) and postherpetic neuralgia (PHN) are attributable to gabapentin. 
Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and 
mice (e.g., spi[INVESTIGATOR_483237], spi[INVESTIGATOR_483238], and acute herpes zoster 
infection model). Gabapentin also decreases pain-related responses after peripheral inflammation 
(carrageenan footpad test, late phase of formalin test), but does not alter immediate pain-related 
behaviors (rat tail flick test, formalin footpad acute phase). The relevance of these models to 
human pain is not known. 
Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but 
has no effect on GABA binding, uptake, or degradation. Gabapentin enacarbil and gabapentin 
have been tested in radioligand binding assays, and neither exhibited affinity for a number of 
other common receptor, ion channel, or transporter proteins. 
In vitro studies have shown that gabapentin binds with high affinity to the α2δ subunit of 
voltage-activated calcium channels; however, the relationship of this binding to the therapeutic 
effects of gabapentin enacarbil in RLS and PHN is unknown. 
1.2 Study Rationale 
Horizant is formulated as an extended-release (ER) formulation of gabapentin enacarbil. The 
primary purpose of this study is to evaluate the abuse potential of gabapentin enacarbil 
immediate-release (GE-IR), the active moiety in Horizant in comparison to placebo and an active 
control with known abuse potential (i.e., alprazolam). 
Gabapentin does not exhibit affinity for benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573] (mu, delta, or kappa), or 
cannabinoid [ADDRESS_709726] of the individuals described in these reports had a history of 
poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other 
substances. 
The Arbor drug safety database through November 2020 contained 728 reports categorized under 
drug abuse. Of these, 16 (2.2%) were attributed to Horizant, 452 (62%) to gabapentin, 242 
(33.2%) to Regnite (gabapentin enacarbil reports in Japan), and 20 (2.7%) to gabapentin 
enacarbil (6 of these are specified as ER in the narrative). Of the [ADDRESS_709727] misuse and use issue cases (n=9, 56%). These cases 
involved consumers who reported independently adjusting their dose to manage their 
symptoms/tolerability. This includes 6 who decreased the dose, 1 who increased the dose, and 2 
with unspecified changes. This was followed in frequency by [CONTACT_268582] (n=4, 25%). The 
Protocol No: AR26.3031.[ADDRESS_709728] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 17 of 81
overdose cases involved reports of feeling "out of sorts", jittery, dizzy, and sleepy after taking 
1200 mg; short-term memory loss after increasing the dose from 1200 mg to 1800 mg; and 
sedation after taking 600 mg instead of 300 mg. The fourth overdose case involved a male who 
took several pi[INVESTIGATOR_543626]. 
Two cases of Horizant-related abuse involved accidental overdose (n=2). One was associated 
with a suspected drug interaction that increased the side effects of her seizure medication. The 
second accidental overdose resulted in death. An autopsy and investigation deemed the cause to 
be combined toxicity of multiple drugs (including Percocet, Xanax, alcohol and medical 
marijuana). Dependence (n=1) was reported by a male with a history of addiction to narcotics. 
After an unknown duration of taking Horizant for an unreported indication, he reported addiction 
issues. No further information was received. Horizant reports from the American Association 
Poison Control Centers National Poison Data System Annual Report are included. 
The Regnite cases involved similar events, with intentional product misuse and use issue cases 
accounting for a larger majority of cases (95%). 
Gabapentin abuse cases were different, however. The most common event was toxicity to 
various agents with (93.8%, 424/452). Of the [ADDRESS_709729] (n=73), accidental overdose (n=51), drug abuse (n=37), overdose (n=5), intentional 
product misuse (n=6), and intentional overdose (n=1). Gabapentin enacarbil was reported in 
[ADDRESS_709730] misuse (n=21; including the 6 report also involving toxicity to 
various agents). The remaining reports involved the same terms previously listed and were 
reported no more than 5 times each. Of the gabapentin reports, 65% involved intentional product 
misuse or use issues. The remaining terms, consistent with other products, were reported no 
more than 4 times each. 
In addition, the Food and Drug Administration’s Adverse Event Reporting System (FAERS) 
from October 2012 to December 2016 reportedly contained 634 gabapentinoid abuse-related 
reports (10.2% of all adverse drug event [ADE] reports). Of these, abuse was associated with 
5.7% of total reports for gabapentin ADEs (576 of 10,038) compared to 10.2% of total reports 
for pregabalin ADEs (58 of 571). The abuse-related proportional reporting rate of pregabalin to 
gabapentin is 1.77. Abuse was more common relative to the total ADEs reported with pregabalin 
than gabapentin.[ADDRESS_709731] the central nervous system (CNS), are chemically 
or pharmacologically similar to other drugs with known abuse potential, or produce psychoactive 
effects are required to undergo assessments related to their abuse potential.3, 4 Horizant, a 
CNS -active drug, is currently approved for use in humans as a treatment for moderate to severe 
primary RLS and PHN; however, its abuse potential has not been formally evaluated. 
This study is a randomized, double-blind, active- and placebo-controlled, 5-way crossover 
design, aimed to assess the abuse potential, safety, and PK of Horizant compared with an active 
control and placebo in healthy, nondependent, recreational sedative drug users. The overall 
design is consistent with [LOCATION_002] (US) Food and Drug Administration (FDA) guidelines for 
human abuse potential (HAP) assessment.4, 5 
Protocol No: AR26.3031.[ADDRESS_709732] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 18 of 81
Because of inter-individual variability in subjective responses, HAP studies are typi[INVESTIGATOR_483241]-blind crossover studies including the investigational drug and active 
control, as well as placebo. The active control should be a controlled drug, ideally from the same 
pharmacological class as the study drug, which has measurable abuse liability established 
through experimental studies and epi[INVESTIGATOR_75144], such that it will produce a significant, 
dose-dependent increase on measures of subjective effects. The active control provides evidence 
of the sensitivity of the methodology and the validity of the study.6, 7 Therefore, based on the 
observed clinical effects to date, the sedative (benzodiazepi[INVESTIGATOR_050]) class was considered the most 
appropriate pharmacologic class for an active control in this study. A placebo- control is also 
included to control and account for expectancy effects. 
Alprazolam, the active control selected for this study, is a benzodiazepi[INVESTIGATOR_543627]. Historically, alprazolam has been [ADDRESS_709733].33 Alprazolam has been used as an active control in several recent studies at 
doses ranging between 1.5 and 3.0 mg.8, 9, 10, 11 An intermediate dose of 2.0 mg was selected as 
this is the common dose that is used for qualification phases in human abuse potential studies 
and reliably produces significant increases on subjective measures of drug effects (including 
Drug Liking), can be safely administered, and does not impose significant sedation that would 
limit the collection of study measures. In recent studies, alprazolam has been shown to maintain 
study validity on the measure of Drug Liking under the new statistical testing requirements 
outlined in the 2017 FDA guidance for industry.4 Therefore, alprazolam was chosen as a positive 
control that can also reliably maintain study validity. 
A double-blind Qualification phase has been included in this study design as an enrichment 
procedure to ensure that subjects who meet the drug use history criteria can also distinguish the 
subjective effects of the active control (i.e., alprazolam) from placebo. The pharmacologic 
qualification procedure provides more objective confirmation of drug use history, ensures that 
subjects can respond appropriately in a clinical setting, and reduces the chance of a false positive 
response to placebo. The washout between treatments in the Qualification phase is consistent 
with previous studies of this type, and the duration of pharmacodynamic (PD) effects associated 
with alprazolam has been shown to have returned to baseline by 24 hours postdose.8, 9, 10, 11 
In clinical studies conducted to date, adverse events (AEs) of sedation, somnolence, and 
dizziness have been the most commonly reported in both healthy subject and patient studies of 
Horizant. Thus, subjects will be healthy individuals with previous nontherapeutic (recreational) 
experience with sedative drugs. These subjects represent the population at greatest risk for abuse 
of the drug and can provide meaningful ratings of the drug experiences with a lower risk of false 
negative results; therefore, they are the population with the most face validity. 
In addition to the requirement that subjects are “history qualified” (i.e., history of recreational 
sedative drug use), subjects will also be required to pass a pharmacologic qualification (see 
above). In an abuse potential study, a negative result with a non-drug-using population can be 
considered inconclusive, since these subjects often do not like the effects of drugs that are readily 
abused by [CONTACT_483285].4, 7 
Protocol No: AR26.3031.[ADDRESS_709734] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 19 of 81
The mean T ½ of alprazolam is 11.2 hours. The minimum 3-day washout interval between the 
Qualification phase and Treatment phase is considered sufficient given the PD effects associated 
with alprazolam return to baseline by 24 hours postdose, as stated above. . 23 Given the T ½ of 
gabapentin when receiving GE-IR (4.38 - 5.47 hours) by [CONTACT_177146], the minimum 3-day 
interval between dosing during the treatment periods will ensure sufficient washout of GE-IR 
and alprazolam. 
Based on the pharmacokinetic (PK) profile of gabapentin, the 24-hour assessment period 
following administration of study drug during the Treatment phase is sufficient to evaluate the 
safety and tolerability and to capture the profile of pharmacodynamic (PD) effects. 
The selection of subjective abuse potential measures in this study, including the use of maximum 
(peak) effect (E max) of the “at this moment” Drug Liking visual analog scale (VAS; administered 
as a bipolar scale) as a primary endpoint, is consistent with regulatory guidelines.[ADDRESS_709735]’s 
willingness to take the drug again.  
Pharmacokinetic and safety assessments suitable for evaluating risks associated with 
administration of doses of GE-IR will also be included. 
1.[ADDRESS_709736] guidelines for HAP studies indicate that doses above the anticipated therapeutic dose 
should be tested.4, 7, 12 The current US FDA Guidance for Industry on the assessment of abuse 
potential of drugs recommends including multiple doses of the study treatment in the HAP study, 
ranging from therapeutic to supratherapeutic.4 
The GE-IR doses in this study will include 200 mg, 450 mg and 750 mg doses, in order to 
evaluate the dose response of the drug. These doses of GE-IR correspond to the C max values 
produced by [CONTACT_483286] 600 mg, 1200 mg, and 1800 mg gabapentinin healthy 
individuals. 
The dose of alprazolam selected (2 mg) is consistent with doses previously evaluated in human 
abuse potential studies.8, 9, 10, [ADDRESS_709737] been administered in human abuse potential studies, 
and this dose has relatively strong sedative effects; therefore, subjects who experience 
unarousable sedation during the Qualification phase at a dose of 2 mg will not be enrolled. The 
2 mg dose is expected to demonstrate separation from placebo based on previous data with 
alprazolam and will ensure that subjects are able to tolerate (with respect to sedation) and 
respond appropriately in the Treatment phase. 
All doses of study drug will be administered in the fasted state. A previous study of alprazolam 
demonstrated the rate of alprazolam absorption was slower after administration during fed 
relative to fasted conditions. In this study, the mean maximum observed plasma concentration 
(Cmax) decreased approximately 25%, and time to C max (Tmax) was delayed approximately 
1.5 hours when food was administered before dosing (4.0 hours [range=2.53-6.03 hours] versus 
2.5 hours [range=0.75-4.01 hours]).34 
Protocol No: AR26.3031.[ADDRESS_709738] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 20 of 81
1.4 Risk/Benefit Assessment 
1.4.1 Known Potential Risks 
The safety of GE-IR in doses ranging from 350 mg to 2800 mg has been evaluated in 88 healthy 
subjects in 2 clinical trials (single ascending dose trial [XP 006] and multiple ascending dose 
trial [XP 018]). 
In study XP 006, dizziness was the most common AE experienced and appeared to be dose-
dependent; occurring mostly at doses from [ADDRESS_709739] common AE experienced, followed by 
[CONTACT_12704], somnolence and nausea. Adverse events were mild with frequencies that were possibly 
dose-related. 
The doses of GE-IR administered in this study are not anticipated to induce any potential risk to 
the subjects. Single dose studies using up to 2800 mg of GE-IR (XP 006) as mentioned above did 
not result in any respi[INVESTIGATOR_483242]. The safety monitoring 
practices employed by [CONTACT_256563]’ safety and to detect any 
treatment-emergent AEs (TEAEs). 
The following safety measures will be monitored continuously for signs of respi[INVESTIGATOR_113021] 1 hour prior to dosing up to approximately 6 hours following dosing in the Treatment 
phase: 
 end-tidal CO 2 (EtCO 2) monitoring 
 blood oxygen saturation (SpO 2) monitoring 
 respi[INVESTIGATOR_113022] [ADDRESS_709740] in monitoring respi[INVESTIGATOR_2606], change in oxygenation, and change in ventilation.21, 22, 23, 24 Monitoring EtCO 2 has been 
shown to be more sensitive in detection of respi[INVESTIGATOR_543628].25 
In the clinical setting, respi[INVESTIGATOR_483245], decreased SpO 2 levels, or elevated EtCO 2 levels26 and, therefore, these 
measures are appropriate to monitor respi[INVESTIGATOR_2341]. 
Additional safety measures implemented at predose and specified timepoints postdose will 
include the collection and documentation of AEs and vital signs (i.e., systolic and diastolic blood 
pressure, pulse rate, respi[INVESTIGATOR_697], oral temperature, SpO 2), and EtCO 2. Subjects will be 
determined as healthy for inclusion into the study based on measures of clinical laboratory 
testing, vital signs, medical history, C-SSRS, physical examination, and ECG. 
1.4.[ADDRESS_709741] medical benefit from participation in this trial. 
Protocol No: AR26.3031.[ADDRESS_709742] Number: ABO-P1-[ADDRESS_709743] 
crossover design. Subjects will be randomized to 1 of the 10 pre-specified treatment sequences in 
which they will receive the following 5 treatments in a crossover manner (1 per treatment period) 
and blinded fashion: 
 Placebo 
 Alprazolam 2 mg (active control) 
 GE-IR 200 mg 
 GE-IR 450 mg 
 GE-IR [ADDRESS_709744] day of each treatment period followed by [CONTACT_4002], PK, and safety assessments for 
up to 24 hours postdose. Subjects will be discharged from the investigational site approximately 
24 hours after the final dose if deemed medically stable for discharge by [CONTACT_2413]. 
Study assessments will be performed at the timepoints outlined in the Schedule of Activities 
(Table 1). 
The maximum duration of subject participation will be approximately 49 days, including 
screening. 
Protocol No: AR26.3031.[ADDRESS_709745] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 24 of 81
Figure 1. Study Schema 
 Screening  
  
 Admission within 30 days of screening 
  
 Randomized Double-Blind Qualification Phase   
(Crossover treatments on Day 1 and Day 3)  
  
 Alprazolam 2 mg ↔ 
48 hours Placebo  
  
 ≥[ADDRESS_709746] Treatment phase treatment 
  
Randomized Double-Blind Treatment Phase  
(5 crossover treatment periods) 
  
GE-IR 
200 mg ↔ 
≥3 days GE-IR 
450 mg ↔ 
≥3 
days GE-IR 
700 mg ↔ 
≥3 days Placebo 
Control ↔ 
≥3 days Alprazolam Active 
Control 
2 mg 
  
 
Note: the sequence of treatments shown is for illustration of the overall design and does not necessarily represent an 
actual treatment sequence. Refer to Table [ADDRESS_709747] dose of the Treatment phase. 
Protocol No: AR26.3031.[ADDRESS_709748] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 25 of 81
3.2 Study Treatments 
The following treatments will be administered with approximately 240 mL of room temperature 
water in the morning under fasted conditions during the Qualification phase: 
 Placebo: A single dose of placebo to match alprazolam (2 lactose 100 mg tablets over-
encapsulated in one Swedish Orange Opaque AAEL-DB capsule) will be administered 
orally. 
 Active Control: A single 2 mg dose of alprazolam (2 × 1 mg tablets over-encapsulated in 
one Swedish Orange Opaque AAEL-DB capsule) will be administered orally.  
The following treatments will be administered with approximately 240 mL of room temperature 
water in the morning under fasted conditions during the Treatment phase: 
 Placebo: Three placebo capsules to match GE-IR + 1 placebo capsule to match 
alprazolam [2 × over-encapsulated placebo tablets in one Swedish Orange Opaque 
AAEL-DB capsule] will be administered orally.  
 Active Control: A single 2 mg dose of over-encapsulated alprazolam (2 × 1 mg tablets 
over-encapsulated in one Swedish Orange Opaque AAEL-DB capsule) + 3 placebo 
capsules to match GE-IR will be administered orally.  
 A single 200 mg dose of GE-IR (1 × 200 mg immediate-release [IR] capsule + 2 placebo 
capsules to match GE-IR capsule + 1 placebo capsule to match alprazolam [2 × 1 mg 
placebo tablets over-encapsulated in one Swedish Orange Opaque AAEL-DB capsule]) 
will be administered orally.  
 A single 450 mg dose of GE-IR (2 × 225 mg immediate-release [IR] capsule + 1 placebo 
capsule to match GE-IR capsule + 1 placebo capsule to match alprazolam [2 × over-
encapsulated placebo tablets in one Swedish Orange Opaque AAEL-DB capsule]) will be 
administered orally.  
 A single 700 mg dose of GE-IR (3 × 233.3 mg immediate-release [IR] capsules + 
1 placebo capsule to match to alprazolam [2 × over-encapsulated placebo tablets in one 
Swedish Orange Opaque AAEL-DB capsule]) will be administered orally. 
[ADDRESS_709749] study drug administration. 
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
subsequently randomly assigned to treatment in the Qualification phase. Subjects who enter the 
Qualification phase and fail to qualify for the Treatment phase will be considered qualification 
failures. 
Protocol No: AR26.3031.[ADDRESS_709750] Number: ABO-P1-[ADDRESS_709751] meet all of the following criteria to be enrolled: 
1. Provision of signed and dated informed consent form (ICF), 
2. Stated willingness to comply with all study procedures and availability for the duration of 
the study, 
3. Male or female, between 18 and 55 years of age, inclusive, 
4. Current nondependent, recreational drug user who has used sedative drugs for 
recreational (nontherapeutic) purposes (i.e., for psychoactive effects) at least [ADDRESS_709752]’s lifetime and at least once in the 12 weeks before screening, 
5. Body mass index (BMI) within 18.0 kg/m2 to 36.0 kg/m2, inclusive, 
6. If female, meets 1 of the following criteria: 
a) If of childbearing potential agrees to use [ADDRESS_709753] dose of the study drug. An acceptable method of 
contraception includes 1 of the following: 
 Abstinence from heterosexual intercourse, 
 Hormonal contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implantable/insertable 
hormonal birth control products, transdermal patch), 
 Intrauterine device (IUD; with or without hormones), 
 
Or 
 
b) If of childbearing potential agrees to use a double barrier method (e.g., condom and 
spermicide) during the study and for at least [ADDRESS_709754] dose of study drug. 
 
Or 
c) If of non-childbearing potential, defined as surgically sterile (i.e., has undergone 
complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a 
postmenopausal state (i.e., at least 1 year without menses without an alternative 
medical condition and confirmed follicle stimulating hormone (FSH) ≥ 40 mIU/mL 
prior to the first study drug administration), 
7. If male and engaging in sexual activity that has the risk of pregnancy must agree to use a 
double barrier method (e.g., condom and spermicide) and agree to not donate sperm 
during the study and for at least [ADDRESS_709755] dose of the study medication, a 
male who has a pregnant partner shall be excluded, 
Protocol No: AR26.3031.[ADDRESS_709756] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 27 of 81
8. Healthy, as determined by [CONTACT_237062], 
physical examination, 12-lead ECG, vital signs or clinical laboratory (including 
hematology, clinical chemistry, urinalysis, and serology [screening visit only]) at 
screening visit and admission, as applicable, in the opi[INVESTIGATOR_85292], 
9. Negative Covid-[ADDRESS_709757] prior to each admission, as applicable. 
4.2 Exclusion Criteria 
Subjects meeting the following criteria will be excluded from participation: 
1. History of significant hepatic, renal, cardiovascular, pulmonary, hematologic, 
neurological, psychiatric, gastrointestinal, endocrine, immunologic, ophthalmologic, or 
dermatologic disease of any etiology (including infections), 
2. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that 
may affect drug bioavailability with the exception that cholecystectomy is permitted at 
the discretion of an investigator, 
3. Presence of any significant respi[INVESTIGATOR_483250] (e.g., upper respi[INVESTIGATOR_4375], sleep apnea, emphysema, asthma) at 
screening (subjects with acute respi[INVESTIGATOR_543629]), 
4. Personal or family history (first degree relatives) of allergy, hypersensitivity, or drug rash 
with eosinophilia and systemic symptoms (DRESS) syndrome to gabapentin enacarbil, 
gabapentin or any drug product including anti-convulsants (e.g., alprazolam, 
carbamazepi[INVESTIGATOR_050]) or related drugs (e.g., other benzodiazepi[INVESTIGATOR_1651]) or known excipi[INVESTIGATOR_543630] (e.g., lactose),  
5. History of sensitivity to or poor tolerance of gabapentin enacarbil, gabapentin, 
pregabalin, or alprazolam, 
6. Female who is lactating at screening, 
7. Female who is pregnant according to the pregnancy test at screening or prior to the first 
study drug administration or planning to become pregnant within [ADDRESS_709758] study drug administration, 
8. History of substance or alcohol dependence (excluding nicotine and caffeine) within the 
past 2 years, as defined by [CONTACT_92678], 4th 
Edition (DSM-IV), and/or subject has been in a drug or alcohol rehabilitation program 
within the last 2 years, 
Protocol No: AR26.3031.[ADDRESS_709759] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 28 of 81
9. Subjects with positive UDS results at screening and admission will be assessed for 
inclusion at the discretion of an Investigator. If tetrahydrocannabinol (THC) is positive at 
admission to the Qualification phase and Treatment phase, as applicable, a cannabis 
intoxication evaluation will be done by [CONTACT_543643], rescheduled, or discontinued at the discretion of an investigator. 
Other positive test results should be reviewed to determine if the subject may be 
rescheduled, in the opi[INVESTIGATOR_871], 
10. Is a heavy smoker (>20 cigarettes per day or nicotine-equivalent) and/or is unable to 
abstain from smoking or unable to abstain from the use of prohibited nicotine-containing 
products for at least 1 hour before and 6 hours after study drug administration (including 
e-cigarettes, pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine topi[INVESTIGATOR_113040], nicotine gum, or 
nicotine lozenges), 
11. Regularly consumes excessive amounts of caffeine or xanthines within 30 days prior to 
screening, defined as greater than 6 servings (1 serving is approximately equivalent to 
120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day, 
12. History of suicidal ideation within 24 months or suicidal behaviour within 2 years of 
screening, showing suicidal tendency as per the Columbia Suicide Severity Rating Scale 
(C-SSRS) administered at screening ( APPENDIX 7 ), or is currently at risk of suicide in 
the opi[INVESTIGATOR_85292], 
13. Presence of clinically significant ECG abnormalities at the screening visit, as defined by 
[CONTACT_35846], NOTE: QT corrected according to Fridericia's formula (QTcF) 
interval of >450 msec in male subjects or >470 msec in female subjects will be 
exclusionary. The ECG may be repeated once for confirmatory purposes if the initial 
value obtained exceeds the limits specified, 
14. Has creatinine clearance ≤60 ml/min as calculated by [CONTACT_16424]-Gault equation, 
15. Any history of tuberculosis, 
16. Positive screening results to human immunodeficiency virus (HIV) 1 and 2 antibodies, 
hepatitis B virus surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) tests, 
17. Intake of an investigational product (IP) within 30 days or 5 times the half-life 
(whichever is longer) prior to screening, 
18. Use of any prescription drugs (with the exception of hormonal contraceptives or hormone 
replacement therapy) in the [ADDRESS_709760] as healthy, 
Protocol No: AR26.3031.[ADDRESS_709761] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 29 of 81
19. Use of over-the-counter (OTC) products (including herbal preparations and supplements) 
within [ADDRESS_709762] study drug administration, with the exception of ibuprofen 
or acetaminophen, 
20. Donation of plasma in the 7 days prior to screening, 
21. Blood donation (excluding plasma) of approximately [ADDRESS_709763] meet the following criteria to be considered eligible for enrollment in the 
Treatment phase of the study: 
1. Peak score in response to alprazolam 2 mg greater than that of placebo on Drug Liking 
VAS (difference of at least 15 points), with a peak score of at least 65 points for 
alprazolam. 
2. Acceptable placebo response based on Drug Liking VAS (peak score between 40 and 
60 points, inclusive). 
3. Acceptable overall responses to alprazolam and placebo on the subjective measures, as 
judged by [CONTACT_91048]. 
4. Able to tolerate the [ADDRESS_709764] difficulty differentiating between bipolar and unipolar VAS 
(e.g., making errors such as selecting 50 as neutral for a unipolar scale) or difficulty 
distinguishing between "at this moment" and "next-day" measures during the 
Qualification phase may be permitted into the Treatment phase, and will undergo 
additional training on the difference between the scale types. Additional training sessions 
will be documented in source files. 
Protocol No: AR26.3031.[ADDRESS_709765] Number: ABO-P1-[ADDRESS_709766] treatment administration, inclusion/exclusion criteria will govern the subjects to 
be dosed. Subjects withdrawn before first treatment administration will not be followed up and 
will not undergo ET assessments. Other safety assessments may be performed if required. 
Subjects are free to withdraw their consent to participate in the study at any time, without 
prejudice. The reason for their withdrawal or for deciding to end their participation will be 
documented. 
4.4.[ADDRESS_709767]’s premature withdrawal from the study and record the 
reason in the subject’s study documents. 
Attempts should be made to have such subjects complete the ET assessments. ET assessments 
should be performed as soon as possible after the last study treatment administration. 
The blind may be broken only in emergency situations, where knowledge of the treatment that 
the subject received is necessary for safety management (section 5.2.4) 
Details of reasons for removal of subjects will be recorded, reported to the sponsor and 
documented in the clinical study report (CSR). 
For subjects who are lost to follow-up (i.e., those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), an investigator should 
show "due diligence" by [CONTACT_762] 
(e.g., dates of telephone calls, registered letters). 
Protocol No: AR26.3031.[ADDRESS_709768] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 31 of 81
4.5 Lifestyle and/or Dietary Requirements 
 Subjects will be prohibited from consuming food or beverages containing grapefruit, 
pomelo, pomegranate, star fruit, Seville orange, poppy seeds, and quinine (i.e., tonic 
water) for [ADDRESS_709769] study treatment and throughout the study. 
 Subjects will be prohibited from consuming alcohol for [ADDRESS_709770] for alcohol and/or a drug screen may be performed if requested by [CONTACT_98225]. If a subject presents with a positive alcohol test or drug screen at any visit 
after the screening visit, the subject may be rescheduled at the discretion of an 
investigator. If THC is positive at check-in, a cannabis intoxication evaluation will be 
done by [CONTACT_2413], and inclusion will be at the investigator’s discretion. 
 Subjects will be prohibited from consuming food or beverages containing xanthines 
(i.e., tea, coffee, cola drinks, energy drinks or chocolate) for [ADDRESS_709771] 
study treatment through clinic discharge. 
 Subjects will eat only the food provided by [CONTACT_113102]. 
 Subjects will be instructed to abstain from strenuous physical activity for 48 hours prior 
to screening, each study treatment, and during inpatient stays at the investigational site. 
 During the study, smokers will abstain from smoking for at least [ADDRESS_709772] 6 hours after drug administration at each study period. Subjects will not be 
permitted to use other nicotine-containing products (including nicotine topi[INVESTIGATOR_113040], 
nicotine gum, or nicotine lozenges). 
 Subjects will be instructed to refrain from driving, operating machinery, or engaging in 
hazardous activities until they and an investigator are convinced the study drug is not 
impairing their judgment and/or ability to perform skilled tasks. 
 Female subjects of childbearing potential will have to take appropriate measures to 
prevent pregnancy as described in section 4.1. It is the subject’s responsibility to notify 
the CRU if a pregnancy occurs from the end of their study participation until [ADDRESS_709773] dose of the study drug. 
 Males who are sexually active will be expected to use an acceptable contraceptive 
regimen and not to donate sperm from the first administration of the study drug, during 
the study, and until at least [ADDRESS_709774] been completed. 
Systemic contraceptives and hormone replacement therapy are permitted for female subjects. 
Subjects will be asked about any new medications (including herbal preparations and 
supplements) taken between screening and admission to the clinic, and between the Qualification 
Protocol No: AR26.3031.[ADDRESS_709775] Number: ABO-P1-[ADDRESS_709776] is discharged during this interim period. Information on any 
concomitant medications administered after consent will be collected throughout the study. All 
medications and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy and blood 
transfusions) administered after the subject has received the study treatment must be listed in the 
subject case report form (CRF) and related conditions (e.g., AEs) documented. The drug name 
[CONTACT_483313]. An investigator and/or the sponsor will decide whether the subject 
will be permitted to remain in the study, depending on the drug used, the time of drug intake, etc. 
5 STUDY TREATMENTS 
5.1 Investigational Products 
GE-IR capsules will be provided by [CONTACT_456]. The lot number and the measured content of the 
dosage form, when available, of each formulation will be included in the final report. 
5.1.1 Gabapentin Enacarbil 
GE-IR capsules will be provided by [CONTACT_543642], LLC for oral administration, and 
will be provided in opaque capsules of a suitable size to contain all study doses in order to 
maintain the blind during dosing. 
Placebo capsules matched to GE-IR will be supplied by [CONTACT_456]. The weight is matched to 
the sponsor’s GE-IR capsule and the composition is the same, including excipi[INVESTIGATOR_840]. 
5.1.2 Alprazolam 
Xanax (alprazolam) is manufactured by [CONTACT_4618], Inc. and will be supplied as [ADDRESS_709777] of 2 × 1 mg tablets over-encapsulated. 
Placebo to match alprazolam tablets will be over-encapsulated 2 × [ADDRESS_709778] Management 
5.2.1 Packaging, Labeling and Dispensing 
The sponsor will be responsible for ensuring that GE-IR is manufactured in accordance with 
applicable current Good Manufacturing Practice (cGMP) regulations and requirements. 
The study drug will be labeled according to the requirements of local law and legislation. The 
study drug will be dispensed according to International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP) by [CONTACT_47365]’s pharmacy, unless the sponsor supplies the pharmacy with 
pre-labeled individual dosing samples. 
Protocol No: AR26.3031.[ADDRESS_709779] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 33 of 81
5.2.2 Storage and Handling 
Once received, all study drugs will be stored in the CRU’s pharmacy. 
GE-IR capsules and placebo should be stored at 25°C with excursions between 15°C and 30°C 
allowed. Both placebo to match alprazolam and alprazolam should be stored between 15°C and 
30°C. All study drugs should be kept in a tightly closed container, with provided desiccants, to 
protect from moisture. The products should not be used if expi[INVESTIGATOR_483255]. 
The CRU’s pharmacy will maintain an inventory record of the study drugs received, stored (in a 
secure restricted area), and dispensed. Study drugs will be provided to study subjects only. 
5.2.[ADDRESS_709780] that the study is balanced. Once generated, the randomization 
codes will be final and will not be modified. 
Subjects who sign the ICF and are randomized but do not receive a study treatment in the 
Treatment phase may be replaced. Subjects who sign the ICF, are randomized and receive a 
study treatment in the Treatment phase, and subsequently withdraw, or are withdrawn or 
discontinued from the study, may be replaced. 
[IP_ADDRESS] Qualification Phase 
Subjects who enter the Qualification phase will be assigned, in ascending order, a qualification 
randomization number to identify the sequence of their treatments ( Table 2). 
Table 2. Sample Qualification Phase Sequences 
Treatment Sequence Day 1 Day 3 XY X Y 
YX Y X 
Treatment X: Placebo 
Treatment Y: Alprazolam 2 mg (active control) 
A minimum 3-day washout will be required between the last dose in the Qualification phase and 
the first dose of the Treatment phase.  
[IP_ADDRESS] Treatment Phase 
For the Treatment phase, qualified subjects will be randomized to [ADDRESS_709781] 
based on their randomization code. Subjects will receive all 5 treatments in the order specified by 
[CONTACT_543644] 5 × 5 Williams square design ( Table 3). 
Protocol No: AR26.3031.[ADDRESS_709782] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 34 of 81
Table 3. Sample Treatment Phase Sequences 
Treatment 
Sequence Period 1 Period 2 Period 3 Period 4 Period 5 
ABECD A B E C D 
BCADE B C A D E 
CDBEA C D B E A 
DECAB D E C A B 
EADBC E A D B C 
DCEBA D C E B A 
EDACB E D A C B 
AEBDC A E B D C 
BACED B A C E D 
CBDAE C B D A E 
Treatment A: Placebo 
Treatment B: Alprazolam 2 mg (active control) 
Treatment C: GE-IR 200 mg 
Treatment D: GE-IR 450 mg 
Treatment E: GE-IR 700 mg 
Protocol No: AR26.3031.[ADDRESS_709783] Number: ABO-P1-[ADDRESS_709784] (or delegate). When all PD assessments during the Qualification phase have 
been completed for each cohort, the randomization will be released to allow for the evaluation of 
qualification criteria. For the Treatment phase, the randomization will remain blinded until all 
the CRFs have been approved and signed. 
The preparation and/or dispensing of the products will be performed by [CONTACT_483292]. 
The randomization code must not be broken except in emergency situations where the 
identification of a subject’s study treatment is required by [CONTACT_543645](s) in the case of a suspected, unexpected SAE 
(S[LOCATION_003]R) report. Randomization information will be held by [CONTACT_394522](s). The date 
and reason for breaking the blind must be recorded. 
5.2.[ADDRESS_709785] (quantity and condition), subject 
dispensing records, and returned or destroyed study product. 
Drug accountability will be performed throughout the trial and at the completion of the trial. 
5.[ADDRESS_709786] the oral/buccal cavity to ensure that the 
study drug was swallowed. 
Food and fluid intake other than water will be controlled for each confinement period and for all 
subjects. Water will be provided as desired until at least 1-hour predose. Water will be allowed 
beginning at least [ADDRESS_709787] 4 hours after each dose. 
5.3.1 Treatment Compliance 
The study drug(s) will be dispensed only to eligible subjects and administered under the 
supervision of study personnel. Treatment compliance will be verified according to the site’s 
standard operating procedures (SOPs). 
Protocol No: AR26.3031.[ADDRESS_709788] Number: ABO-P1-[ADDRESS_709789] 6 hours following drug administration, avoiding vigorous exertion. However, 
should AEs occur at any time, subjects may be placed in an appropriate position. During this 
interval subjects will be permitted, under supervision, to get up (e.g., to use the washroom 
facilities). Subjects will not engage in strenuous activity at any time during the confinement 
periods. 
6 STUDY PROCEDURES 
Unless otherwise stated in this protocol, the SOPs of the study facilities, which are available for 
all activities relevant to the quality of the study, will be followed during this study. Procedure 
windows, including PK/PD sample collection windows, will be documented in a separate clinical 
document. 
An overview of the study activities for each subject is detailed in Table 1. 
Pharmacodynamic data collection (vital signs then subjective measures) is to be prioritized, 
followed by [CONTACT_483280], when clinical activities are scheduled to occur at the same time. 
Subjects will be confined to the clinical site from Day -[ADDRESS_709790] dose of the Treatment phase. 
Subjects will be discharged on Day 14 of the Treatment phase. 
Any deviation from protocol procedures shall be noted in the source documentation and 
compi[INVESTIGATOR_543631]. 
6.1 Safety Assessments 
Safety assessments will include physical examination, C-SSRS, vital signs (i.e., systolic and 
diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral temperature, SpO 2), 12-lead ECG, 
clinical laboratory tests, and AE monitoring. Continuous SpO [ADDRESS_709791]’s well-being and history of relevant past medical 
events/experiences. Medical history will include all demographic data (age, gender, race, body 
weight, height, and BMI) and baseline characteristics. Smoking habits will also be recorded. 
Protocol No: AR26.3031.[ADDRESS_709792] Number: ABO-P1-[ADDRESS_709793] 
dose of study treatment in the Qualification phase will be recorded as medical history. If the 
condition meets the criteria for an SAE it will be reported as described in section 7.6. Medical 
history conditions that worsen and are judged to be clinically significant will be recorded as AEs. 
6.1.2 Recreational Alcohol/Drug Use 
A lifetime history of all drug use, including alcohol, will be collected as scheduled in Table 1. 
History, including drug preference (i.e., drug of choice), frequency of use, and date of last use 
will be collected using reported drug names and drug class (e.g., cannabinoids, depressants, 
dissociative anesthetics, hallucinogens, opi[INVESTIGATOR_113049], and stimulants). 
DSM-IV modules will be included as a part of the recreational drug/alcohol use history and used 
to screen for alcohol and substance dependence. 
6.1.3 Physical Examination 
A physical examination will be performed by a medically qualified and licensed individual as 
scheduled in Table 1. 
The physical examination will include a general review of the following body systems (at 
minimum): general appearance, head, eyes, ears, nose and throat (HEENT), neck/thyroid, 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, neurological, musculoskeletal/extremities, and skin. 
A symptom-oriented physical exam may be conducted as indicated in Table 1, at the discretion 
of an investigator. 
6.1.4 Vital Signs 
Vital signs will be measured as scheduled in Table 1 and will include blood pressure, pulse rate, 
respi[INVESTIGATOR_543632] 2 measures at designated times. 
All vital signs will be interpreted by [CONTACT_483294], abnormal not clinically 
significant (NCS), or abnormal clinically significant (CS). New or worsening abnormalities that 
are judged to be clinically significant will be recorded as AEs. 
Vital signs will be measured after being in supi[INVESTIGATOR_1662]-supi[INVESTIGATOR_21683] 5 minutes. 
[IP_ADDRESS] Continuous and Spot Oxygen Saturation 
Assessments of respi[INVESTIGATOR_483258] [ADDRESS_709794]’s fingertip. Continuous oxygen saturation will be monitored through a 
capnography monitor. 
SpO2 will be monitored for alarms continuously up to [ADDRESS_709795] dosing, as scheduled in Table 1. Any SpO 2 event that is deemed clinically 
significant will be reported as an AE if it meets the criteria of significance defined in 
section 6.1.8. 
Protocol No: AR26.3031.[ADDRESS_709796] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 38 of 81
[IP_ADDRESS] Continuous and Spot End-Tidal CO [ADDRESS_709797] dosing, as 
scheduled in Table 1. Any EtCO 2 event that is deemed clinically significant will be reported as 
an AE if it meets the criteria of significance defined in section 6.1.8. 
[IP_ADDRESS] Continuous and Spot Respi[INVESTIGATOR_543633] 1. Spot respi[INVESTIGATOR_543634] [ADDRESS_709798] 5 minutes. 
All abnormal ECGs will be interpreted by [CONTACT_483295], or abnormal CS in 
source documents. New or worsening abnormalities that are judged to be clinically significant 
will be recorded as AEs. 
6.1.6 Laboratory Evaluations 
Laboratory evaluations will be performed as scheduled in Table 1. 
The laboratory evaluations to be conducted for this study are presented in  APPENDIX 6 . The 
total blood volume for screening and safety assessments will be approximately 15 mL. 
Each abnormal value will be interpreted by [CONTACT_483295], or abnormal CS. 
New or worsening abnormalities that are judged to be clinically significant will be recorded as 
AEs. 
Urine samples to be collected during the course of this study include pregnancy tests and drug 
screens as outlined in Table 1. 
Protocol No: AR26.3031.[ADDRESS_709799] Number: ABO-P1-[ADDRESS_709800] panels (not required for subject safety). Only test results required by [CONTACT_543646]/or abnormal results will be entered in the clinical database and reported in the CSR, based on 
report requirements. 
6.1.7 Columbia Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS is a questionnaire designed for the assessment of suicidal ideation and behavior in 
adolescents and adults. 
To monitor for a history of (the past 2 years/24 months to present) or the emergence during study 
participation of suicidal ideation and behavior, subjects will undergo C-SSRS evaluations at the 
timepoints indicated in Table 1. 
The questionnaire must be administered by [CONTACT_543647]. See APPENDIX 7 for a sample C-SSRS –
Baseline/Screening version assessment and APPENDIX [ADDRESS_709801] becomes suicidal during the study, an investigator or medically qualified 
sub-investigator should provide the appropriate treatment and/or referral to the subject, and 
record as an AE. 
6.1.8 Assessment of Respi[INVESTIGATOR_543635]: 
 An increase in EtCO 2 to >50 mmHg 
 A reduction in O 2 saturation to <90% 
 A reduction in respi[INVESTIGATOR_80753] <6 breaths per minute 
All alarms will be assessed for clinical significance and reported as AEs, as applicable. 
Supplemental oxygen will be given as medically necessary. 
6.1.9 Rescue Therapy 
The clinical study site is equipped with emergency equipment and supplies that correspond with 
the level of risk associated with this study. In case of a medical emergency or an SAE requiring 
medical intervention, emergency equipment and supplies will be available and will include, but 
may not be limited to, stocked crash carts, oxygen source, suction pump, and defibrillator. 
Emergency medication (e.g., flumazenil, diphenhydramine, epi[INVESTIGATOR_238], methylprednisolone, 
ranitidine, rescue medication required for advanced cardiac life support [ACLS]) may be 
administered if deemed necessary by [CONTACT_91048]. If required, subjects will be 
transported to a hospi[INVESTIGATOR_307]. 
During the Qualification and Treatment phases, the principal investigator (PI) or designee will be 
on-site at the time of study drug administration until at least 6 hours postdose. ACLS-certified 
staff will be present on site and an investigator will be readily available by [CONTACT_756]. 
Protocol No: AR26.3031.[ADDRESS_709802] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 40 of 81
When not available on-site, the PI [INVESTIGATOR_113069]-call until the end of the study. While 
confined in the CRU, subjects will be supervised by [CONTACT_113123]/or paramedics. Dedicated 
nurses and/or paramedics will be available to monitor AEs and perform safety measures. 
The date and time of rescue medication administration as well as the name [CONTACT_543653]. 
6.2 Pharmacokinetic Assessments 
A total of 14 blood samples will be collected following each dose in the Treatment phase for PK 
assessments. The complete blood sampling schedule is presented in  Table 4. 
Table 4. Pharmacokinetic Blood Sampling Schedule 
Sample No Nominal Time* 
(hours) 
01 0.0 
02 0.5 
03 1 
04 1.5 
05 2 
06 2.5 
07 3 
08 4 
09 5 
10 6 
11 7 
12 8 
13 10 
14 24 
* Nominal times listed are relative to the time of study treatment administration. 
Blood samples will be collected by [CONTACT_230491] a labeled tube containing the 
appropriate anticoagulant as specified by [CONTACT_85332]. As an option to the subject, or 
if judged necessary by [CONTACT_49885], blood samples may be collected using a catheter, which 
will be placed in the vein of the subject. 
The time of PK blood sample collection will be calculated relative to the time of dose 
administration. The actual time of all PK blood draws will be recorded and reported for all 
subjects. Each subject will be dosed at the same time in each period and all activities 
(e.g., scales, meals) will be based on that dosing time. Blood volume required for PK 
assessments will be included in the total blood volume reported in the informed consent. 
Protocol No: AR26.3031.[ADDRESS_709803] Number: ABO-P1-[ADDRESS_709804] difficulty differentiating between 
bipolar and unipolar VAS (e.g., making errors such as selecting 50 as neutral for a unipolar 
scale) or difficulty distinguishing between "at this moment" and "next-day" measures during the 
Qualification phase will undergo additional training on the difference between the scale types. 
Additional training sessions will be documented in source files. 
Testing conditions for PD assessments should remain as consistent as possible across treatment 
periods. Subjects will be monitored carefully to ensure that they are completing the PD 
assessments appropriately; all reasonable attempts should be made to rouse subjects who fall 
asleep during testing cycles. If subjects cannot complete the PD assessments in a timely manner 
prior to the next required procedure or timepoint due to an AE, testing will be aborted. 
6.3.1 Subjective Effects 
[IP_ADDRESS] Visual Analogue Scales 
All VASs will be scored on a 100-point scale, as shown in Table 5. The VASs may be 
administered as bipolar or unipolar scales, as appropriate, and the choice is determined by [CONTACT_543648]. Bipolar scales ask about the neutrality, the 
direction and the intensity of a subjective opi[INVESTIGATOR_1649], whereas unipolar scales only ask about the 
extremity or intensity of a subjective opi[INVESTIGATOR_1649]. When VASs are administered as bipolar scales, a 
neutral point equal to 50 is embedded within the scale (e.g., Drug Liking, Overall Drug Liking, 
Take Drug Again, Drowsiness/Alertness VAS). The neutral point reflects a state whereby a 
subject is experiencing neither negative nor positive effects (e.g., neither dislike nor like the 
effects of the drug) and is labeled with an anchor, such as “neither like nor dislike.” When VASs 
are administered as unipolar scales, anchors will be presented using text such as “Not at all” 
(score = 0) to “Extremely” (score = 100; e.g., Good, Bad, High, and Any Effects VASs). 
Unipolar scales do not include a neutral point but rather, a rating of “0” reflects the complete 
absence of a subjective effect while a rating of “100” reflects the maximum presence of a 
subjective effect (e.g., No Good Effects = 0, Extremely Good Effects = 100). Scales that refer 
specifically to drug (e.g., Drug Liking, Good Effects VAS, Bad Effects VAS, and Any Effects 
VAS) are not administered at predose. 
Protocol No: AR26.3031.[ADDRESS_709805] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 42 of 81
Table 5. Visual Analog Scale (VAS) Descriptions 
Scale 
Interpretation Include 
Predose Type of 
Scale Description Question Text Response 
Anchors 
Balance No Bipolar Drug Liking At this moment, my 
liking for this drug is 0: Strong 
disliking 
50: Neither like 
nor dislike 
100: Strong 
liking Balance No Bipolar Overall Drug Liking Overall, my liking for 
this drug is 
Balance No Bipolar Take Drug Again I would take this drug 
again 0: Definitely 
would not 
50: Neither 
would nor would 
not 
100: Definitely 
would 
Positive Yes Unipolar High At this moment, I am 
feeling high 
0: Not at all 
100: Extremely Positive No Unipolar Good Effects At this moment, I feel 
good drug effects 
Negative No Unipolar Bad Effects At this moment, I feel 
bad drug effects 
Other No Unipolar Any Effects At this moment, I feel 
any drug effect 
Other Yes Unipolar Feeling Drunk At this moment, I am 
feeling drunk 
Other  Yes Bipolar Drowsiness/Alertness At this moment, my 
mental state is 0: Very drowsy 
50: Neither 
drowsy nor alert 
100: Very alert 
Other Yes Bipolar Relaxation/Agitation At this moment, my 
mental state is 0: Very relaxed 
50: Neither 
relaxed nor 
agitated 
100: Very 
agitated 
Protocol No: AR26.3031.[ADDRESS_709806] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 43 of 81
[IP_ADDRESS] Questionnaires 
The ARCI MBG and PCAG scales will be administered as scheduled in  Table 1. 
The 49-item ARCI is a shortened version (49 true-false items) compi[INVESTIGATOR_186484].37 from 
the 550-item Addiction Research Center Inventory (ARCI) originally developed by [CONTACT_186508].38,39 
This version contains 5 scales, which measure the following effects: Euphoria -- Morphine-
Benzedrine Group (MBG) scale; Stimulant effects -- Amphetamine (A) scale and Benzedrine 
Group (BG) scale; Dysphoria -- Lysergic Acid Diethylamide (LSD) scale; and Sedation --
Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) scale. Subjects indicate their responses 
by [CONTACT_20683] “False” or “True.” One point is given for each response that agrees with the scoring 
direction on the scale (i.e., True items receive a score of 1 if the answer is “True;” no points are 
given when the answer is opposite to the scoring direction). 
The following 2 scales will be administered: 
 Pentobarbital Chlorpromazine Alcohol Group – PCAG 
 Morphine Benzedrine Group – MBG 
The items pertaining to the ARCI MBG and ARCI PCAG scales are presented below: 
Questions Contributing to ARCI MBG & PCAG Scales  Scale PCAG MBG 
1. My speech is slurred.  T  
2. I am not as active as usual.  T  
3. I have a feeling of just dragging along rather than coasting.  T  
4. I feel sluggish.  T  
5. My head feels heavy.  T  
6. I feel like avoiding people, although I usually do not feel this way.  T  
7. I feel dizzy.  T  
8. It seems harder than usual to move around.  T  
9. I am moody.  T  
10. People might say that I am a little dull today.  T  
11. I feel drowsy.  T  
12. I am full of energy.  F  
13. Today I say things in the easiest possible way.   T 
14. Things around me seem more pleasing than usual.   T 
15. I have a pleasant feeling in my stomach.   T 
16. I feel I will lose the contentment that I have now.   T 
Protocol No: AR26.3031.[ADDRESS_709807] Number: ABO-P1-[ADDRESS_709808].  F  
T = True item 
F = False item 
Responses to individual items will be included. If one of the individual items is missing, the 
associated scale(s) score will not be calculated. 
6.3.2 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) 
The MOAA/S is an observer-rated measure of alertness/sedation that is used widely in clinical 
research. It is based on the following 6 items, rated on a scale from 5 (not sedated) to 
0 (unarousable): 
The Observer’s Assessment of Alertness/Sedation Scale (OAA/S) was developed to measure the 
level of alertness in subjects who are sedated.36 The OAA/S is a reliable validated measure and 
was shown to be sensitive to different levels of sedation and is composed of 4 assessment 
categories that include responsiveness, speech, facial expression, and eyes. The Modified 
Observer's Assessment of Alertness/Sedation Scale (MOAA/S) includes only the Responsiveness 
assessment category. It is easy and quick to administer (less than 1 minute). The subjects’ level 
of responsiveness is measured in a 5-point Likert scale: 
Protocol No: AR26.3031.[ADDRESS_709809] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 45 of 81
 
Responsiveness Score 
Responds readily to name [CONTACT_154992] 5 (Alert) 
Lethargic response to name [CONTACT_154992] 4 
Responds only after name [CONTACT_248794]/or repeatedly 3 
Responds only after mild prodding or shaking 2 
Does not respond to mild prodding or shaking 1 (Deep Sleep) 
[ADDRESS_709810] a causal relationship with the 
treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically 
significant abnormal clinical laboratory finding, for example), symptom, or disease temporally 
associated with the use of an investigational product, whether or not related to the investigational 
product. 
A suspected adverse reaction (SAR) is any AE for which there is a reasonable possibility the 
drug caused the AE. ‘Reasonable possibility’ means there is evidence to suggest a causal 
relationship between the drug and the AE. A suspected adverse reaction implies a lesser degree 
of certainty about causality than adverse reaction, which means any AE caused by a drug. 
Regarding marketed medicinal products, an adverse drug reaction is defined as a response to a 
drug which is noxious and unintended and which occurs at doses normally used in man for 
prophylaxis, diagnosis, or therapy of disease or for modification of physiological function. 
An AE may be: 
 A new illness, 
 Worsening of a concomitant illness, 
 An effect of the study drug including comparator; it could be an abnormal clinical 
laboratory value as well as a significant shift from baseline within normal range which an 
investigator considers to be clinically important. 
Surgical procedures themselves are not AEs. They are therapeutic measures for conditions that 
required surgery. The condition for which the surgery is required is an AE, if it occurs or is 
detected during the study period. Planned surgical measures permitted by [CONTACT_154575](s) leading to these measures are not AEs, if the condition(s) was 
(were) known before the start of study treatment. In the latter case, the condition should be 
reported as medical history. 
Protocol No: AR26.3031.[ADDRESS_709811] Number: ABO-P1-[ADDRESS_709812] medical occurrence that at any dose: 
 Results in death, 
 Is life-threatening, 
 Requires inpatient hospi[INVESTIGATOR_1081], 
 Results in persistent or significant disability or incapacity (defined as a substantial 
disruption of a person’s ability to conduct normal life functions), 
 Is a congenital anomaly or birth defect, 
 Is an important medical event (including development of drug dependence or drug abuse) 
that may jeopardize the subject or may require intervention to prevent one of the other 
outcomes listed above (according to medical judgment of an investigator). 
7.2 Severity Assessment 
All AEs will be graded as mild, moderate, or severe according to the following definitions: 
Mild: Causing no limitation of usual activities; the subject may experience transient slight 
discomfort. 
Moderate: Causing some limitation of usual activities; the subject may experience annoying 
discomfort. 
Severe: Causing inability to carry out usual activities; the subject may experience intolerable 
discomfort or pain. 
Every effort will be made to obtain an adequate evaluation of the severity. 
7.3 Causality Assessment 
An investigator will determine the relationship of any AE to the study drug using the guidelines 
presented in Table 6. 
Protocol No: AR26.3031.[ADDRESS_709813] Number: ABO-P1-[ADDRESS_709814]’s clinical state or concomitant therapi[INVESTIGATOR_014]. 
Furthermore, the AE appears with some degree of certainty to be 
related, based on the known therapeutic and pharmacolog ic actions or 
AE profile of the investigational product. 
In case of cessation or reduction of the dose the AE may abate or 
resolve and it may reappear upon rechallenge. 
No Reasonable Possibility Evidence exists that the AE has an etiology other than the 
investigational product. 
For SAEs, an alternative causality must be provided (e.g., pre existing 
condition, underlying disease, intercurrent illness, or concomitant 
medication). 
 
7.[ADDRESS_709815] visit will require an appropriate evaluation and 
follow-up until the AE has been resolved or a reasonable explanation for its persistence found, or 
is deemed mild and safely resolving. 
It is an investigator’s responsibility to ensure subjects experiencing adverse events receive 
appropriate follow-up, treatment where required, and that every action is well-documented. 
Classification of AEs will be performed by [CONTACT_9313] (SOC) and preferred term (PT) 
using the Medical Dictionary for Regulatory Activities (MedDRA), version 22.0 or higher. 
Concomitant medications will be coded using the World Health Organization Drug Dictionary-
Enhanced (WHO-DDE March 2019 or later). 
Protocol No: AR26.3031.[ADDRESS_709816] Number: ABO-P1-[ADDRESS_709817] shall be reported to the sponsor within 24 hours of the 
knowledge of its occurrence by [CONTACT_483298] (for pregnancies occurring during the 
course of the study or up to 30 days following the end of the study). Because of the possibility 
the fetus/embryo could have been exposed to the study drug through the parent and for the 
subject’s safety, the pregnancy will be followed up to determine its outcome, including 
spontaneous or voluntary termination, details of birth, presence or absence of any birth defects, 
congenital anomalies, or maternal and/or newborn complications. 
The pregnancy will be recorded and reported by [CONTACT_483299]. Pregnancy 
follow-up will also be properly recorded to ensure quality and completeness of the data 
belonging to the study drug and will include an assessment of the possible causal relation 
between the study drug and any pregnancy outcome. Any SAE experienced during pregnancy 
will be reported on an SAE Report Form. 
7.[ADDRESS_709818](s). Information not available at the time of the initial report (e.g., an end date for the AE, 
laboratory values received after the report, or hospi[INVESTIGATOR_44458]) must be documented. 
All follow-up information must be reported as soon as the relevant info is available, in the same 
manner as the initial report. 
If an SAE occurs to a subject during this study, the SAE report and relevant medical records 
should be faxed at the time of the report to Arbor Safety Inbox  or scanned and 
emailed . The SAE may also be reported by [CONTACT_543649] . 
An SAE will be considered “unexpected” if the AE is not listed in the US product inserts 
(USPIs) or is not listed at the specificity or severity that has been observed; or, if an investigator 
brochure is not required or available, is not consistent with the risk information described in the 
general investigational plan or elsewhere in the current application. "Unexpected," as used in this 
definition, also refers to AEs that are mentioned in the USPIs as occurring with a class of drugs 
or as anticipated from the pharmacological properties of the drug, but are not specifically 
mentioned as occurring with the particular drug under investigation. 
The CRU will determine whether any serious, unexpected, related AE must be reported to the 
institutional review board (IRB). If so, the event will be reported via fax or email within 
15 calendar days of an investigator or staff becoming aware of the event. 

Protocol No: AR26.3031.[ADDRESS_709819] Number: ABO-P1-[ADDRESS_709820] be reported in an expedited manner to the 
applicable regulatory agencies. If so, the sponsor will report the event to those agencies and to all 
participating investigators. 
If reports of any new and unexpected AEs become available to the sponsor during the clinical 
portion of this study, the sponsor will advise the CRU, through its clinical investigator, of those 
events. If required, the sponsor will report to the applicable regulatory authorities. 
8 DATA ANALYSIS AND STATISTICAL METHODS 
8.1 Analysis Populations 
8.1.1 Qualification Phase 
[IP_ADDRESS] Qualification Randomized Population 
The Qualification Randomized population will include all subjects who are assigned a 
randomization number in the Qualification phase. 
[IP_ADDRESS] Qualification Safety Population 
The Qualification Safety population will include all subjects who are randomized into the 
Qualification phase and receive at least 1 dose of either the study drug or placebo. 
8.1.2 Treatment Phase 
[IP_ADDRESS] Randomized Population 
The Randomized population will include all subjects who are assigned a randomization number 
in the Treatment phase. 
[IP_ADDRESS] Safety Population 
The Safety population will include all subjects who are randomized into the Treatment phase and 
receive at least 1 dose of 1 of the study drugs or placebo. 
[IP_ADDRESS] Completer Population 
All subjects in the Safety population who complete all [ADDRESS_709821] sufficient data for evaluation of the primary endpoint (based on a 
blinded review of data prior to database lock) will be included in the Completer population. 
Subjects who do not have at least 1 observation within 2 hours of T max for each treatment for 
Drug Liking VAS will be excluded from the Completer population. 
[IP_ADDRESS] Modified Completer Population 
All subjects in the Completer population, excluding problematic subjects with unreliable 
responses which can alter study results, will be included in the Modified Completer population. 
For the Drug Liking VAS scale, the following elimination criteria will be used to define the 
Modified Completer population. 
a) Similar E max scores (within a 5-point difference) for a subject across all study treatments 
(including placebo) 
OR 
Protocol No: AR26.3031.[ADDRESS_709822] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 50 of 81
b) Emax for placebo > 60 AND the E max(placebo) – E max(positive control) ≥ 5 
Criterion a) and b) will be applied to the Drug Liking VAS data on the Completer population. If 
no subjects are excluded when these criteria are applied, then the Modified Completer population 
is the same as the Completer population. 
[IP_ADDRESS] Pharmacokinetic (PK) Population 
All subjects in the Safety population who receive at least [ADDRESS_709823] 1 PK 
concentration after dosing will be included in the PK population. 
8.2 Appropriateness of Measures 
The selected PD measures will assess positive and negative subjective drug effects associated 
with the abuse potential of this drug. These subjective measures are consistent with guidelines 
for HAP studies4 and are similar to those used in previous studies. Although data from all 
measures will be considered in the assessment of abuse potential, the Drug Liking VAS has been 
selected as the primary endpoint for practical purposes (such as calculating power and assessing 
qualification eligibility), as it is considered [ADDRESS_709824]’s global assessment of the drug and have 
face validity for predicting continued use of a drug. High VAS has also been selected as a key 
secondary endpoint because it has been shown to be sensitive in capturing the positive subjective 
effects of test drugs. Additional secondary endpoints assess other subjective effects of the drug 
that may help with interpretation of the data. 
Standard PK parameters will be evaluated to confirm plasma concentrations and the PK profile 
of GE-IR in the PK population. Standard measures of safety will be included to monitor the 
safety and tolerability of the GE-IR doses used in the study. 
8.[ADDRESS_709825] allocation (i.e., inclusion in the Modified Completer population). If for a given PD 
measure, the predose value is missing, calculation of CFB min and TA_AOE will not be possible, 
and the subject will not be included in the Modified Completer population for that PD endpoint. 
If the actual date and/or time of a postdose PD assessment is unknown, but there is a result at that 
timepoint, the value will be used in descriptive statistics of treatment by [CONTACT_483302], 
and PD endpoint by [CONTACT_483303]_AUE and 
TA_AOE which need actual time from dose in order to be calculated. 
If the actual collection time of a postdose PK sample is unknown, but a valid concentration value 
has been measured, the sample will be set to missing in the PK analysis and will be presented in 
Protocol No: AR26.3031.[ADDRESS_709826] Number: ABO-P1-[ADDRESS_709827] to Break the Blind Form, and in the Statistical Analysis Plan (SAP). 
8.4 Demographic Data and Other Baseline Characteristics 
8.4.1 Qualification Phase 
All subjects who are randomized into the qualification phase will be entered into the database. 
Disposition tables and listings will be presented for all subjects in the Qualification Randomized 
population. Demographics and baseline characteristics (sex, age, race, ethnicity, body weight, 
height, BMI) will be summarized for the Qualification Safety population. Qualification passes 
and failures will be listed separately. 
8.4.2 Treatment Phase 
A disposition table will be presented for all subjects randomized to the Treatment phase. 
Demographics and baseline characteristics (sex, age, race, ethnicity, body weight, height, BMI), 
recreational drug use history, alcohol use history, and smoking history will be summarized using 
descriptive statistics (n, mean, SD, minimum, median, and maximum for continuous variables, 
and the proportion of subjects for categorical variables) for the Safety population. No formal 
statistical comparison between the groups will be performed. 
Medical history will be listed by [CONTACT_1130]. Medical history will be coded into the most recent 
version of MedDRA available (version 22.0 or later). 
Prior and concomitant medications will be assigned a 12-digit code using the most recent version 
of the World Health Organization drug codes available. Prior and concomitant medications will 
be listed by [CONTACT_1130]. 
The number of subjects in each treatment group will be presented, in addition to the number of 
subjects who complete each treatment period. The reasons for all post-randomization 
discontinuations will be tabulated and grouped by [CONTACT_543650]. All deviations 
related to study inclusion or exclusion criteria, conduct of the trial, subject management, or 
subject assessment will be listed. 
8.5 Pharmacodynamics 
8.5.1 Pharmacodynamic Endpoints 
Pharmacodynamic endpoints will be evaluated as described in Table 7 and all PD data will be 
analyzed using the Modified Completer population. 
Protocol No: AR26.3031.[ADDRESS_709828] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 52 of 81
Table 7. Pharmacodynamic Endpoints  
Description Type Endpoints 
Drug Liking Bipolar VAS Emax, Emin, TEmax, TEmin, and 
TA_AUE  
Overall Drug Liking Bipolar VAS Emax 
Take Drug Again Bipolar VAS Emax 
High Unipolar VAS Emax, TEmax, and TA_AUE 
Good Effects Unipolar VAS Emax, TEmax, and TA_AUE  
Bad Effects Unipolar VAS Emax, TEmax, and TA_AUE  
Any Effects Unipolar VAS Emax, TEmax, and TA_AUE  
Feeling Drunk Unipolar VAS Emax, TEmax, and TA_AUE 
Drowsiness/Alertness Bipolar VAS Emin, TEmin, and TA_AOE  
Relaxation/Agitation Bipolar VAS Emin, TEmin, and TA_AOE  
Addiction Research Center 
Inventory (ARCI) Morphine-
Benzedrine Group (MBG) Scale Questionnaire score Emax, TEmax, and TA_AUE  
ACRI Pentobarbital–
Chlorpromazine–Alcohol Group 
(PCAG) Scale Questionnaire score Emax, TEmax, and TA_AUE 
Modified Observer’s Assessment 
of Alertness/Sedation (MOAA/S) Observer’s score Emin, CFBmin, and TA_AOE 
CFBmin= change from baseline to minimum effect, E max= maximum (peak) effect, E min=minimum effect, 
TA_AOE= time-averaged area over the effect-time curve, TA_AUE=time-averaged area under the effect-time 
curve, TE max=time of maximum (peak) effect, TE min=time of minimum effect, VAS=Visual Analog Scale 
8.5.2 Pharmacodynamic Statistical Methodology 
Drug Liking and Take Drug Again VAS E max from the Qualification phase will be summarized 
by [CONTACT_543651]. The data will be 
evaluated to confirm that an appropriate population was selected for the Treatment phase. 
During the Treatment phase, PD values at each timepoint will be summarized by [CONTACT_186492]. Derived endpoints will be summarized by 
[CONTACT_186493]. 
[IP_ADDRESS] Primary Analysis 
Pharmacodynamic endpoints for the Treatment phase (E max, Emin, CFBmin, TA_AUE and 
TA_AOE, as appropriate) will be analyzed using a mixed-effect model if the residuals are 
normally distributed. The model will include treatment, period, treatment sequence, and 
first-order carryover effect (where applicable) as fixed effects, and the baseline (predose) 
measurement as a covariate (where applicable). If the variance among treatments is 
homogeneous, subject will be considered a random effect; if the variance among treatments is 
heterogeneous, the default variance components (VC) variance structure block will be used for 
Protocol No: AR26.3031.[ADDRESS_709829] Number: ABO-P1-[ADDRESS_709830]. 
The null and alternative hypotheses for this analysis are shown below: 
H0: distribution of residuals is normal vs. H a: distribution of residuals is not normal 
If the residuals from the mixed-effect model are normally distributed, e.g., p-value ≥ 0.05, it will 
be determined if carryover effects should be included. 
When conducting drug abuse potential studies, Chen and Tsong14 have recommended the 
inclusion of first-order carryover as a fixed effect in the mixed-effect model. The adoption of this 
conservative approach would address possible effects associated with the subjective nature of 
these studies. Carryover effects are defined as the treatment administered in the previous 
treatment period. As there are no carryover effects in treatment period 1, placebo will be used in 
this period. If the carryover effect is found to be non-significant at alpha ≥ 0.25, then the term 
will be dropped from the mixed-effects model. If the carryover effect is found to be significant at 
alpha < 0.25, it will be included in the model. 
If the normality assumption of the model is satisfied, least-square means, standard errors (SEs), 
and 1-sided 95% or 2-sided 95% or 90% confidence intervals (CIs) for treatments and treatment 
differences will be derived from the mixed-effect model. P-values will be provided for the effects 
and the contrasts. 
If the normality assumption of the model is not satisfied, the distribution of the paired difference 
for each contrast will be examined in terms of normality and skewness. Each paired difference 
will be investigated for normality using the Shapi[INVESTIGATOR_2152]-Wilk W-test. If the p-value for the 
distribution of the paired difference is normal, that is, p-value ≥ 0.05, a paired t-test will be used. 

Protocol No: AR26.3031.[ADDRESS_709831] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 55 of 81
 
 
 
               
 
 
               
 
 
              
These hypotheses will be applied to the primary endpoint, Drug Liking VAS E max. 
Although a margin of 15 has been selected for Hypothesis 1 to ensure consistency with the 
Qualification phase criteria, subjects are expected to provide lower responses in the Treatment 
phase as compared to the Qualification phase.19, 31 Therefore, if the difference between the 
positive control and placebo does not meet the recommended criterion for validity (i.e., δ 1= 15), 
a secondary planned analysis will be performed (refer to section [IP_ADDRESS]) A margin of 11 points is 
considered appropriate for Hypothesis 3 based on an analysis of Drug Liking VAS E max data.15 
Further details will be described in the SAP. . 
For study validity purposes, the primary endpoint, E max for Drug Liking VAS, will be compared 
between the positive control (alprazolam 2 mg) and placebo.  
   
 
 If statistically significant, it will confirm 
the sensitivity of the study and allow for the comparison of the other pairwise comparisons 
shown below. The hypotheses can be expressed as follows: 
         
where μ C is the mean for the positive control, alprazolam, and μ P is the mean for placebo, and 
will be applied to the following contrast: 
  
To assess whether the test drug has less abuse potential than the positive control, the null 
hypothesis will be that the mean difference in Drug Liking E max between alprazolam and GE-IR 
is less than or equal to [ADDRESS_709832] the alternative hypothesis that the mean difference in Drug 
Liking E max between alprazolam and GE-IR is greater than 0. 

Protocol No: AR26.3031.[ADDRESS_709833] Number: ABO-P1-[ADDRESS_709834] drug, 
GE-IR, will be: 
         
where μ C is the mean for the positive control, alprazolam, and μ T is the mean for the test drug, 
GE-IR, and will be applied to the following contrasts: 
The hypothesis for comparison between the test drug, GE-IR, and placebo will be: 
         
where μ T is the mean for the test drug, GE-IR, and μ P is the mean for placebo, and will be 
applied to the following contrasts: 
  
  
  
A significance level of 0.05 will be used for all 1-sided tests; 1-sided 95% confidence intervals 
will be presented. For 2-sided tests, a significance level of 0.1 will be used 32 with 2-sided 90% 
confidence intervals. No adjustments for p-values will be made to account for multiple 
comparisons. 
[IP_ADDRESS].[ADDRESS_709835] drug in humans: 
         
         
         

Protocol No: AR26.3031.[ADDRESS_709836] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 58 of 81
The hypothesis for comparison between the positive control, alprazolam and placebo will be: 
         
where μ C is the mean for the positive control, alprazolam, and μ P is the mean for placebo, and 
will be applied to the following contrast: 
  
The hypothesis for comparison between the positive comparator, alprazolam, and the test drug, 
GE-IR, will be: 
         
where μ C is the mean for the positive control, alprazolam, and μ T is the mean for the test drug, 
GE-IR, and will be applied to the following contrasts: 
  
  
  
The hypothesis for comparison between the test drug, GE-IR, and placebo will be: 
         
where μ T is the mean for the test drug, GE-IR, and μ P is the mean for placebo, and will be 
applied to the following contrasts: 
  
  
  
A significance level of 0.05 will be used for Hypotheses 1 and 2, and a significance level of 0.1 
will be used for Hypothesis 3.32 For Hypotheses 1 and 2, 2-sided 95% confidence intervals will 
be presented while 2-sided 90% confidence intervals will be presented for Hypothesis 3. No 
adjustments for p-values will be made to account for multiple comparisons. 
[IP_ADDRESS] Secondary Analysis 
Although a margin of [ADDRESS_709837] lower responses with alprazolam and higher 
responses with placebo in the Treatment phase as compared to the Qualification phase, 19,31 
particularly for lower abuse potential drugs such as benzodiazepi[INVESTIGATOR_1651] (i.e., Schedule IV drugs). 
Therefore, in the case that the difference between the active control and placebo does not meet 

Protocol No: AR26.3031.[ADDRESS_709838] Number: ABO-P1-[ADDRESS_709839] 15 points, secondary analysis will be performed. 
Details of the secondary analysis will be described in the SAP. 
8.6 Pharmacokinetics 
The PK analysis will be carried out according to Altasciences SOPs. Pharmacokinetic data 
handling and analysis will be further detailed in the SAP. 
8.6.1 Measurements Below the Lower Limit of Quantitation 
Concentration values below the lower limit of quantitation (LLOQ) associated with predose and 
postdose collection times will be replaced with zero for the non-compartmental analyses (NCA). 
Concentration values below the LLOQ will be replaced with 0 for mean PK profile 
representations  as well as for descriptive statistic calculations. 
8.6.2 Actual Time 
Analysis will be based on the actual sampling times, except for predose samples, which will 
always be reported as 0, regardless of time deviations. 
The individual concentration/time profiles will be presented using actual sampling times whereas 
the mean concentration/time profiles and tables presenting summary statistics of 
concentration-time series will be presented using nominal sampling times. 
Actual times will be listed in the report. 
8.6.3 Noncompartmental Analysis (NCA) 
The following configuration for the NCA analysis (with Phoenix® WinNonlin® version 8, or 
higher) will be used: 
   
    
   
Reason for exclusion of AUC: In the case where less than 3 consecutive measurable 
concentrations are observed, the AUC parameters will not be estimated. 
The PK parameters for gabapentin are presented in Table 8. 

Protocol No: AR26.3031.[ADDRESS_709840] Number: ABO-P1-[ADDRESS_709841] measurable (positive) observed concentration 
8.6.4 Pharmacokinetic Statistical Methodology 
[IP_ADDRESS] Descriptive Statistics 
Descriptive statistics of the individual concentration data and derived parameters will be 
calculated with the build-in Phoenix® WinNonlin® platform and displayed with the same 
precision as received from the bioanalytical laboratory. 
Precision for individual values will be display as follows: 
 Cmax and AUC will be displayed with the same precision as the raw PK concentration 
data 
 Parameters associated with time will be displayed with 2 decimal places 
Summary statistics will be displayed with the same precision as the individual values, with the 
exception of number of observations (N) and coefficient of variation (CV%) which will be 
presented with [ADDRESS_709842], respectively. 
Descriptive statistics will be calculated for concentrations at each individual timepoint and for all 
PK parameters. Individual concentrations, and PK parameters obtained from the NCA will be 
summarized per treatment group using the following descriptive statistics: N, minimum, 
arithmetic mean, geometric mean, median, maximum, standard deviation (SD), CV%. 
[IP_ADDRESS] Statistical Analysis 
No formal statistical analysis of PK data will be performed. 
8.7 Safety 
8.7.1 Safety Endpoints 
For the Treatment phase, safety endpoints will include a summary of the incidence of AEs, 
SAEs, as well as descriptive summary and statistics of the safety parameters (clinical laboratory 
values, vital signs [i.e., systolic and diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral 
temperature, SpO 2], continuous SpO 2 monitoring, continuous EtCO 2 monitoring, ECGs, C-SSRS, 
and physical examination findings. 
Protocol No: AR26.3031.[ADDRESS_709843] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 61 of 81
8.7.2 Safety Analysis 
The clinical laboratory tests and the measurements of vital signs, continuous SpO 2 and EtCO 2 
monitoring, ECGs, C-SSRS and physical examination parameters will be used to perform the 
safety statistical analysis. 
8.7.3 Safety Statistical Methodology 
[IP_ADDRESS] Qualification Phase 
The Qualification Randomized population will be used to list all AEs occurring in the 
Qualification phase. Qualification passes and failures will be listed separately. 
[IP_ADDRESS] Treatment Phase 
Analysis of safety assessments will be performed using the Safety population. Assessment of 
safety will be based on the incidence of AEs, AEs resulting in discontinuation, and SAEs by 
[CONTACT_3148]. AE summaries will be provided showing the number and percentage of subjects who 
experienced at least 1 TEAE during the Treatment phase. TEAEs will also be tabulated by 
[CONTACT_483307]. These summaries will be 
presented by [CONTACT_49240] (Medical Dictionary for Regulatory Activities 
[MedDRA], version 22.0 or higher). SAEs and AEs resulting in discontinuation will be 
summarized separately. All AEs will be listed by [CONTACT_543652]. 
Laboratory data collected during the Treatment phase will be summarized by [CONTACT_483309]. Descriptive statistics (n, mean, SD, minimum, median, and maximum) 
and the number of subjects with laboratory test results below, within, and above normal ranges 
will be tabulated by [CONTACT_765]. Abnormal findings in laboratory data will be listed. 
Treatment phase vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], SpO 2) and EtCO 2 will be 
analyzed as minimum, maximum, and final postdose values since the analyses of these extremes 
are more meaningful than analyses of individual timepoints. Vital signs will be summarized 
using descriptive statistics (n, mean, SD, minimum, median, and maximum). Abnormal findings 
in vital signs data will be listed.  
12-Lead ECG data during the Treatment phase (absolute values in heart rate and PR, QRS, QT, 
and QTcF intervals) will be summarized by [CONTACT_483310] (n, 
mean, SD, minimum, median, and maximum). Overall ECG interpretation will be summarized 
(normal; abnormal, non-clinically significant; and abnormal, clinically significant). Abnormal 
findings in ECG data will be listed. 
Physical examination abnormal results will be listed by [CONTACT_3598]. Baseline and since last 
visit scores from the C-SSRS questionnaire will be listed. No summaries will be provided. 
8.8 Planned Interim Analyses 
No formal interim analyses will be performed. 
Protocol No: AR26.3031.[ADDRESS_709844] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 62 of 81
8.9 Determination of Sample Size 
As reported in an unpublished HAP study evaluating doses of 1.5 mg and 3.0 mg of alprazolam, 
the mean paired difference (SD) for Drug Liking VAS E max VAS between alprazolam 1.5 mg 
and placebo was 26.3 (18.62). For alprazolam 3.0 mg vs. placebo, the mean difference (SD) was 
26.6 (17.83). A margin of 15, with a correlation of 0, and an upper-tailed test with a significance 
level of 0.05 results in 48 completers for the comparison of alprazolam 1.5 mg vs. placebo, and 
42 completers for the comparison alprazolam 3.0 mg vs. placebo. The more conservative sample 
size estimate of 48 subjects will be used. 
Assuming a drop-out rate of approximately 25%, and allowing for missed data and problematic 
subjects as defined for the Modified Completer population, approximately 60 subjects are 
planned for randomization into the Treatment phase in order to achieve a minimum of 
48 completers (at least 4 subjects per 10 treatment sequences). 
Due to potential sedative effects that may prevent subjects from completing measures and 
expected natural attrition, replacement subjects may be considered in order to meet the minimum 
number of completers, in the event that the preplanned attrition rate of 25% is surpassed. 
Subjects will be consecutively randomized into the Qualification phase until the target number of 
60 subjects eligible for participation in the Treatment phase is reached. 
Protocol No: AR26.3031.[ADDRESS_709845] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 63 of 81
9 REFERENCES 
1. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic 
review. Eur Neuropsychopharmacol. 2017 Dec;27(12):1185-1215. doi: 
10.1016/j.euroneuro.2017.08.430. Epub [ADDRESS_709846] 5. 
2. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and 
pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug 
Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 
2019; 953-958. 
3. Draft Guidance for Industry: Assessment of Abuse Potential of Drugs. U.S. Department 
of Health and Human Services. Food and Drug Administration. Center for Drug 
Evaluation and Research. January 2010. 
4. Assessment of Abuse Potential of Drugs. U.S. Department of Health and Human 
Services. Food and Drug Administration. Center for Drug Evaluation and Research. 
January 2017. 
5. US Food and Drug Administration. Guidance for Industry: Abuse-Deterrent Opi[INVESTIGATOR_483264]. Guidance for Industry; April 2015. 
6. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse 
liability assessment. Drug Alcohol Depend. 2003; 70([ADDRESS_709847]):S13-40. 
7. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse 
liability assessment in humans. Drug and Alcohol Depend. 2003; 70(3) Suppl: S41-54.  
8. Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H. Abuse liability 
assessment of eslicarbazepi[INVESTIGATOR_483265]: a phase I randomized controlled trial. Epi[INVESTIGATOR_41744]. 2016; 61:63-71.  
9. Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Randomized, double-blind, 
placebo- and active comparator-controlled crossover study evaluating the abuse potential 
of the antiepi[INVESTIGATOR_543636]. J Clin 
Psychopharmacol. 2017; 37(6):675-683. 
10. Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy 
recreational central nervous system depressant users. Epi[INVESTIGATOR_41744]. 2018a; 78:194-
201. 
11. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) 
in recreational polydrug users: A randomized, double-blind, controlled trial. Epi[INVESTIGATOR_297047]. 2018b; 88:162-171. 
12. Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing 
standards and expectations. Clin Pharmaco Ther. 2008; 83(4):622–626. 
doi:10.1038/sj.clpt.6100492. 
13. Comer SD, Collins ED, MacArthur RB, Fischman MW. Comparison of intravenous and 
intranasal heroin self-administration by [CONTACT_20901]-maintained humans. 
Psychopharmacology. 1999; 143: 327.338. 
Protocol No: AR26.3031.[ADDRESS_709848] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 64 of 81
14. Chen L, Tsong Y. Design and analysis for drug abuse potential studies: issues and 
strategies for implementing a crossover design. Drug Information J. 2007; 41:481-489. 
15. Chen L, Bonson KR. An equivalence test for the comparison between a test drug and 
placebo in human abuse potential studies. J Biopharm Stat. 2013; 23(2):294-306. 
16. Pi[INVESTIGATOR_25192] G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. CONSORT (Consolidated 
Standards of Reporting Trials) Statement. Reporting of Noninferiority and Equivalence 
Randomized Trials-Extension of the CONSORT 2010 Statement. JAMA. 2012; 308(24): 
2594-2604. 
17. Curran, P.J., S.G. West, and J.F. Finch, The robustness of test statistics to non-normality 
and specification error in confirmatory factor analysis. Psychological Methods. 1996; 
1(1): p. 16-29. 
18. Chen L. Principles and methods of statistical assessment of abuse-deterrent opi[INVESTIGATOR_2438]. Ther 
Innov Regul Sci. 2018; 52(1):7-13. 
19. Mills C. Statistical Issues in Abuse-Deterrent Formulation (ADF) and Human Abuse 
Potential (HAP) Studies. CCALC, Abuse Potential Dialogue Session, 12-Oct-2018. 
20. Valium® [Label] (12/16/2016). NDA 013263, Drugs@FDA, FDA Web site. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed January 19, 2020. 
21. Linko K, Paloheimoi M. Inspi[INVESTIGATOR_483272]-tidal oxygen content difference: a sensitive 
indicator of hypoventilation. Crit Care Med 1989;17(4):345-348. 
22. Jabre P, Jacob L, Auger H, et al. Capnography monitoring in nonintubated patients with 
respi[INVESTIGATOR_1506]. Am J Emerg Med 2009;27(9):1056-1059. 
23. Manifold CA, David N, Villers LC, Wampler DA. Capnography for the non-intubated 
patient in the emergency setting. J Emerg Med 2013;45(4):626-632. 
24. Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respi[INVESTIGATOR_483273]: a meta-analysis. J Clin Anesth 2011;23(3):189-196. 
25. Goli V, Webster LR, Lamson MJ, et al. Effects of concurrent intravenous morphine 
sulfate and naltrexone hydrochloride on end-tidal carbon dioxide. Harm Reduct J 
2012;9:13. 
26. Cashman JN, Dolin S J. Respi[INVESTIGATOR_483267]: evidence from published data. Br J Anaesth 2004;93(2):212-223. 
27. Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring 
reveals frequent desaturation and bradypnea during patient-controlled analgesia. Anesth 
Analg 2007;105(2):412-418. 
28. Sivilotti M, Messenger DW, van Vlymen J, et al. A comparative evaluation of 
capnometry versus pulse oximetry during procedural sedation and analgesia on room air. 
CJEM 2010;12(5):397-404. 
Protocol No: AR26.3031.[ADDRESS_709849] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 65 of 81
29. Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability 
of bretazenil, diazepam and alprazolam in humans. Clin Pharmacol Ther 1994; Apr 55 
(4) : 451-63. 
30. Griffiths RR, McLeod DR, Begelow GE, Liebson IA, Roache JD. Relative abuse liability 
of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology 
(Berl) 1984; 84(2) : 147-54. 
31. Chen L, Tolliver J, Calderon S., Chiapperino D. Improving the Design of Qualification 
Phase in Human Abuse Potential Studies. The College on Problems of Drug Dependence 
(CPDD) 81th Annual Scientific Meeting, June 15-19, 2019. 
32. Chen L. Statistical Considerations on Pharmacodynamic Assessment of Human Abuse 
Potential Studies. CCALC, Abuse Potential Dialogue Session, 12-Oct-2018. 
33. Apelt S, Schmauss C, Emrich HM. Preference for alprazolam as opposed to diazepam in 
benzodiazepi[INVESTIGATOR_050]-dependent psychiatric inpatients.Pharmacopsychiatry. 1990 
Mar;23(2):70-5. 
34. Erdman K, Stypi[INVESTIGATOR_61222] D, Combs M, Witt P, Stiles M, Pollock S. Absence of food effect 
on the extent of alprazolam absorption from an orally disintegrating tablet. 
Pharmacotherapy. 2012; 27(8): 1120-1124. 
35. Daniel, W. W. (1990). Applied Nonparametric Statistics, Second Edition, PWS-KENT 
Publishing Company. 
36. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, 
Siegel JL. Validity and reliability of the Observer's Assessment of Alertness/Sedation 
Scale: study with intravenous midazolam. J Clin Psychopharmacol. 
1990 Aug;10(4):244-51. 
37. Martin WR, Sloan JW, Sapi[INVESTIGATOR_186485], Jasinski DR. Physiologic, subjective, and behavioral 
effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and 
methylphenidate in man. Clin Pharmacol Ther 1971;12(2):245–258. 
38. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center 
Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. 
Psychopharmacologia 1963;70:155–166. 
39. Haertzen CA. An Overview of the Addiction Research Center Inventory (ARCI): An 
Appendix and Manual of Scales. Rockville, MD: National Institute on Drug Abuse; 1974. 
Protocol No: AR26.3031.[ADDRESS_709850] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 66 of 81
10 APPENDIX 1: ETHICS 
10.[ADDRESS_709851] 
This protocol and the informed consent form (ICF) will be submitted to an institutional review 
board (IRB) prior to initiation of the study and the study will not start until the board has 
approved the documents. Notification of the board’s approval will be appended to the final 
report. 
10.[ADDRESS_709852] their origins in the Declaration of Helsinki, the International Council for Harmonisation 
(ICH) Guideline E6 for Good Clinical Practice (GCP), the Food and Drug Administration (FDA) 
GCP Code of Federal Regulations (CFR) Title 21 (part 56), the European regulation EU 
536/2014, and the Tri-Council Policy Statement (Canada). 
10.[ADDRESS_709853] will be given a copy of the ICF to read, as 
well as a full explanation of the purpose of the study, the procedures to be carried out, and the 
potential adverse events (AEs). Once this essential information is provided to the subject and an 
investigator or delegate has the conviction the subject understands the implications of 
participating in the study, and if the subject chooses to continue the screening process, they will 
be requested to sign and date a properly executed ICF prior to enrollment. Subjects will be 
assured they may withdraw from the study at any time without jeopardizing their medical care or 
future study participation (for which they may qualify). 
Subjects will be given a signed copy of the ICF. If an amended or revised ICF is introduced 
during the study, each subject’s further consent must be obtained. 
10.[ADDRESS_709854] identifier on all study documents provided to the sponsor. In compliance with federal 
regulations/ICH GCP Guidelines, it is required an investigator and institution permit authorized 
representatives of the company, of the regulatory agency(s), and IRB access to review the 
subject’s original medical records for verification of study-related procedures and data. An 
investigator is obligated to inform the subject that his/her study-related records will be reviewed 
by [CONTACT_31714]-named representatives without violating the subject’s confidentiality. 
Protocol No: AR26.3031.[ADDRESS_709855] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 67 of 81
11 APPENDIX 2: DATA COLLECTION, RETENTION, AND MONITORING 
11.1 Case Report Forms 
The data required by [CONTACT_483311] 2 ways. Source Documents are used in the clinic 
as recording devices during procedures. The data will be transcribed from source into electronic 
data capture software (Medrio) and stored in the secure database for each subject included in a 
clinical trial (i.e., subjects randomized to the Qualification phase which includes qualification 
failures, and subjects randomized to the Treatment phase). 
Data assembled outside the clinic source (i.e., clinical laboratory data, pharmacokinetic [PK] 
concentration data, and pharmacodynamics [PD] measures [e.g., visual analog scale (VAS) 
scores]), will be received from a specified external vendor via an electronic data file. The file 
received will be encrypted (or posted to a secure File Transfer Protocol) and will be stored in a 
secure folder on a server. The electronic data file(s) are independent of the Medrio electronic 
data capture (EDC) data during the conduct of the study. 
The Medrio EDC cleaned data will be reviewed, approved and electronically signed by [CONTACT_28824] [INVESTIGATOR_9232]. The Medrio EDC data will be output in a case report form 
(CRF) format. The external data files will be output in SAS® datasets. At review cycles, tables, 
figures and listings will be provided in rtf format. All data will be included with the final report 
provided to the sponsor. 
11.[ADDRESS_709856] all data 
cleaning activities, monitoring activities and review/approval activities for clinic collected data 
and procedure data. The external data files will be reconciled (to compare the external vendor 
data and Medrio EDC sample collection data). Data Management activities are performed in 
accordance with the Data Management standard operating procedures (SOPs). 
In addition to the cleaning activities, data entered in Medrio EDC will be checked for accuracy 
through quality control (QC) assessments. When the database data is declared to be complete and 
accurate; the database will be locked, and user access removed. 
11.3 Quality Control and Quality Assurance 
Designated personnel from the quality assurance unit(s) of the clinical, PK, PD, and statistical 
facilities will be responsible for maintaining quality assurance (QA) systems to ensure that the 
trial is conducted, and that clinical/PK/PD/statistical data is generated, documented and reported, 
in compliance with the protocol and the integrated addendum to International Conference on 
Harmonisation (ICH) E6: Guideline for Good Clinical Practice E6 (R2). 
Designated personnel from each corresponding operation unit (i.e., clinical, PK, PD, and 
statistical facilities) will be responsible to maintain and assure the QC of all data generated and 
documented in compliance with the protocol and SOPs. 
All parts of the bioanalytical phase of the study and all its documentation will be subject to 
inspection by [CONTACT_113144], 
documented and reported in compliance with the protocol and applicable requirements as 
Protocol No: AR26.3031.[ADDRESS_709857] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 68 of 81
outlined in the Food and Drug Administration (FDA) and Organization for Economic 
Cooperation and Development (OECD) Principles of Good Laboratory Practice (GLP). 
11.[ADDRESS_709858] Retention 
All essential documents and records will be maintained by [CONTACT_113145], 
and for the period specified in the applicable regulatory requirement(s) (FDA Code of Federal 
Regulations [CFR] 312.57 (C)).  
11.[ADDRESS_709859] (IRB)/independent ethics committee 
(IEC) review, and regulatory inspection(s) by [CONTACT_113146]/or virtual, where possible, 
access to source data/documents. 
Protocol No: AR26.3031.[ADDRESS_709860] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 69 of 81
12 APPENDIX 3: ADMINISTRATIVE PROCEDURES 
12.1 Liabilities 
It is the sponsor’s responsibility to guarantee sufficient insurance coverage should any serious 
events or deaths result, either directly or indirectly, from the execution of the present protocol. 
12.2 Adherence to Protocol 
Excluding an emergency situation in which proper treatment is required for the protection, safety 
and well-being of the study subjects, the study will be conducted as described in the approved 
protocol and performed according to International Conference on Harmonisation (ICH)/Good 
Clinical Practice (GCP) and the applicable regulatory requirements. Any deviation from the 
protocol will be recorded and explained. 
If amendments to the protocol and/or amendments or revisions to the informed consent form 
(ICF) are required, the modifications will be documented and submitted to an institutional review 
board (IRB) for approval. 
12.3 Statement of Investigator 
The Food and Drug Administration (FDA) Form 1572, Statement of Investigator [Title 21, CFR 
Part 312], will be signed by [CONTACT_093], and will be kept on file. 
12.4 Delegation of Investigator Duties 
In the context of this protocol, the term ‘an investigator’ includes the Principal Investigator [INVESTIGATOR_543637]-investigator. 
An investigator will ensure all personnel involved in the trial are adequately qualified and 
informed about the protocol, any amendments to the protocol, the study treatments, and their 
trial-related duties and functions. 
An investigator will maintain a list of sub-investigator(s) and other appropriately qualified 
persons to whom he/she delegates significant trial-related duties. 
Should an investigator delegate the supervision of the study drug administration to a designated 
person, this individual must have the appropriate professional-legal qualifications and 
certifications. An investigator should also ensure key staff personnel have the appropriate 
medical qualifications to effectively conduct or supervise any potential resuscitation procedures. 
12.5 Premature Termination or Suspension of a Study 
The sponsor or its representative may terminate the study at any time for scientific or corporate 
reasons. 
If the trial is prematurely terminated or suspended for any reason, the clinical site or an 
investigator (or delegate) should promptly inform the trial subjects, should assure appropriate 
therapy and follow-up for the subjects, and should inform the regulatory authority(ies) and IRB, 
when required. 
Protocol No: AR26.3031.[ADDRESS_709861] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 72 of 81
14 APPENDIX 5: LIST OF ABBREVIATIONS 
Ab Antigen/antibody  
ACLS Advanced cardiac life support  
ADE Adverse drug event  
AE Adverse event  
ALT Alanine aminotransferase  
AOE Area under the effect-time curve  
ARCI Addiction Research Center Inventory  
AST Aspartate aminotransferase  
AUC0-T Area under the concentration-time curve from [ADDRESS_709862]  
CFR Code of Federal Regulations  
cGMP Current Good Manufacturing Practice  
CI Confidence interval  
Cmax Maximum concentration  
CNS Central nervous system  
CRF Case report form  
CRU Clinical research unit  
CS Clinically significant  
CSR Clinical study report  
C-SSRS Columbia Suicide Severity Rating Scale  
CV Coefficient of variation  
DRESS Drug rash with eosinophilia and systemic symptoms  
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition  
ECG Electrocardiogram  
EDC Electronic data capture  
Emax Maximum (peak) effect  
Emin Minimum effect  
ER Extended-release  
Protocol No: AR26.3031.[ADDRESS_709863] Number: ABO-P1-[ADDRESS_709864]  
IU International unit  
IUD Intrauterine device  
kg Kilogram  
LLOQ Lower Limit of Quantitation  
MBG Morphine-Benzedrine Group  
MCV Mean corpuscular volume  
MedDRA Medical Dictionary for Regulatory Activities  
mg Milligram  
MOAA/S Modified Observer’s Assessment of Alertness/Sedation  
N Number of observations  
NCA Noncompartmental analysis  
NCS Not clinically significant  
OECD Organization for Economic Co-operation and Development  
OTC Over-the-counter  
PCAG Pentobarbital–Chlorpromazine–Alcohol Group  
PD Pharmacodynamic  
Protocol No: AR26.3031.[ADDRESS_709865] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 74 of 81
pH The logarithm, on the base 10, of the reciprocal of the hydrogen ion concentration  
PHN Postherpetic neuralgia  
PI [INVESTIGATOR_543638]’s formula  
RLS Restless legs syndrome  
SAE Serious adverse event  
SAP Statistical analysis plan  
SAR Suspected adverse reaction  
SD Standard deviation  
SOC System organ class  
SOP Standard operating procedure  
SpO2 Oxygen saturation   
S[LOCATION_003]R Suspected, unexpected SAE  
T½ Elimination half-life  
TEAE Treatment-emergent adverse event  
TEmax Time of maximum (peak) effect  
TEmin Time of minimum effect  
THC Tetrahydrocannabinol  
Tlast Last measured observable concentration  
Tmax Time of maximum concentration  
US [LOCATION_002]  
USPI [INVESTIGATOR_543639]-DDE World Health Organization Drug Dictionary-Enhanced   
Protocol No: AR26.3031.[ADDRESS_709866] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 75 of 81
15 APPENDIX 6: CLINICAL LABORATORY EVALUATIONS 
Clinical Laboratory Test Panel Description 
General biochemistry: Sodium, potassium, chloride, glucose, blood urea nitrogen (BUN), 
creatinine, bilirubin total, alkaline phosphatase, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and 
albumin  
Endocrinology: Follicle stimulating hormone (FSH; for female subjects) 
Hematology: White cell count with differential (absolute values of neutrophil, 
lymphocyte, monocyte, eosinophil, and basophil), red cell count, 
hemoglobin, hematocrit, mean corpuscular volume (MCV), and 
platelet count 
Serology1: Human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) 
Combo, Hepatitis B (HBsAg (B)) and Hepatitis C (HCV (C))  
Urinalysis: Color, clarity, specific gravity, pH, leukocyte, protein, glucose, 
ketones, bilirubin, blood, nitrite, urobilinogen. Microscopic 
examination will only be performed if the dipstick test is outside of 
the reference range for leukocyte, blood, nitrite or protein 
Urine drug screen: Alcohol, amphetamines, barbiturates, cannabinoids, cocaine, 
opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], and phencyclidine 
Urine OR serum pregnancy test: To be performed for all female subjects 
                                                 
1 Screening visit only. 
Protocol No: AR26.3031.[ADDRESS_709867] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 76 of 81
16 APPENDIX 7: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) –
BASELINE/SCREENING VERSION 
Protocol No: AR26.3031.[ADDRESS_709868] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 77 of 81

Protocol No: AR26.3031.[ADDRESS_709869] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 78 of 81
 

Protocol No: AR26.3031.[ADDRESS_709870] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 79 of 81
17 APPENDIX 8: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) –SINCE 
LAST VISIT VERSION 
Protocol No: AR26.3031.[ADDRESS_709871] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 80 of 81

Protocol No: AR26.3031.[ADDRESS_709872] Number: ABO-P1-904  
 
Version 3.0, 09AUG2021 Page 81 of 81
 
